

(10) International Publication Number
WO 2017/155973 A1(43) International Publication Date
14 September 2017 (14.09.2017)


- (51) **International Patent Classification:**
C12N 15/86 (2006.01) *A61K 48/00* (2006.01)
- (21) **International Application Number:**
PCT/US2017/021124
- (22) **International Filing Date:**
7 March 2017 (07.03.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/304,656 7 March 2016 (07.03.2016) US
- (71) **Applicant:** UNIVERSITY OF IOWA RESEARCH FOUNDATION [US/US]; 112 N Capitol Street, 6 Gilmore Hall, Iowa City, Iowa 52242 (US).
- (72) **Inventors:** ENGELHARDT, John F.; 16 Burr Oak, Iowa City, Iowa 52246 (US). YAN, Ziying; 27 Andrea Court, Iowa City, Iowa 52246 (US).
- (74) **Agents:** PERDOK, Monique, M. et al.; P.O. Box 2938, Minneapolis, Minnesota 55402 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** AAV-MEDIATED EXPRESSION USING A SYNTHETIC PROMOTER AND ENHANCER

AAV-MEDIATED EXPRESSION USING A SYNTHETIC PROMOTER AND ENHANCER

Cross-Reference to Related Applications

5 This application claims the benefit of the filing date of U.S. application Serial No. 62/304,656, filed on March 7, 2016, the disclosure of which is incorporated by reference herein

Statement of Government Rights

 The invention was made with government support under grant HL108902
10 awarded by the National Institutes of Health. The Government has certain rights in the invention.

Background

 Cystic fibrosis (CF) is a lethal, autosomal-recessive disorder that affects at least 30,000 people in the U.S. alone (O'Sullivan et al., 2009). The genetic basis of CF is
15 mutation of a single gene that encodes the cystic fibrosis transmembrane conductance regulator (*CFTR*) (Riordan et al., 1989; Rommens et al., 1989). This results in a defective *CFTR* protein and consequent abnormalities in the transport of electrolytes and fluids in multiple organs (Welsh, 1990; Rowe et al., 2005). The most life-threatening outcome is CF pulmonary disease, which is characterized by viscous mucous
20 secretions and chronic bacterial infections (Welsh, 1990). With improvement in patient care and advances in pharmacologic therapies for CF, the lifespan of CF patients has steadily been extended over the past decades; however, the quality of life for CF patients remains poor, and medications that alleviate pulmonary complications are expensive and efficacious only in select patients. Since lung disease is the major cause
25 of mortality in CF patients and the genetic basis is a single-gene defect, gene therapy for CF lung disease has the potential to cure all CF patients, regardless of their *CFTR* mutation. Thus, clinical trials for CF lung gene therapy were initiated in the mid-1990s. However, all trials to date have been unsuccessful (Sumner-Jones et al., 2010). The underlying reason is that the vectors available for gene transfer to the human airway
30 epithelium (HAE) are inefficient (Mueller & Flute, 2008; Griesenbach & Alton, 2009; Griesenbach et al., 2010).

 Adeno-associated virus (AAV), a member of the human parvovirus family, is a non-pathogenic virus that depends on helper viruses for its replication. For this reason, rAAV vectors are among the most frequently used in gene therapy pre-clinical studies
35 and clinical trials (Carter, 2005; Wu et al., 2006; Daya & Berns, 2008). Indeed, CF lung disease clinical trials with rAAV2 demonstrated both a good safety profile and long persistence of the viral genome in airway tissue (as assessed by biopsy) relative to other gene transfer agents (such as recombinant adenovirus). Nevertheless, gene transfer failed to improve lung function in CF patients because transcription of the rAAV
40 vector-derived *CFTR* mRNA was not detected (Flotte, 2001; Aitken et al., 2001; Wagner et al., 2002; Moss et al., 2007; Duan et al., 2000). These observations are consistent

with later studies on rAAV transduction using an *in vitro* model of the polarized HAE, in which the cells are grown at an air-liquid interface (ALI) (Flotte, 2001; Duan et al., 1998). The poor efficiency of rAAV2 as a vector for *CFTR* expression in the HAE is largely due to two major barriers: 1) inefficient post-entry processing of the virus, and 2) the limited packaging capacity of rAAV.

The initial preclinical studies with rAAV2-*CFTR* that supported the first clinical trial in CF patients were performed in rhesus monkeys. These studies demonstrated that viral DNA and transgene-derived *CFTR* mRNA persisted in the lung for long periods following rAAV2-mediated *CFTR* gene transfer (Conrad et al., 1996). However, later studies comparing the efficiency of rAAV2 transduction between human and rhesus monkey airway epithelial ALI cultures demonstrated that the tropism of rAAV2 for apical transduction was significantly higher in the rhesus monkeys cultures than in their human counterparts (Liu et al., 2007), likely due to species-specific differences in the AAV2 receptors and co-receptors that exist on the apical surface. In studies of polarized HAE, the majority of AAV2 virions were internalized following apical infection, but accumulated in the cytoplasm rather than entering the nucleus (Duan et al., 2000; Ding et al., 2005). One obstacle to the intracellular trafficking required for productive viral transduction is the ubiquitin-proteasome pathway (Duan et al., 2000; Yan et al., 2002); transient inhibition of proteasome activity dramatically enhances transduction (700-fold) of rAAV2-luciferase vectors from the apical surface by facilitating translocation of the vector to the nucleus (Yan et al., 2006). However, the application of proteasome inhibitors to enhance transduction efficiency of rAAV-*CFTR* vectors only marginally improves *CFTR* expression, most likely due to the low activity of the short promoter used in the rAAV-*CFTR* vectors (Zhang et al., 2004). The open reading frame (ORF) of the *CFTR* gene is 4.443 kb, and thus approaches the size of the 4.679 kb AAV genome. Although the AAV capsid can accommodate content in excess of its native DNA genome, its maximum packaging capacity is approximately 5.0 kb (Dong et al., 1996), and transgene expression from vectors exceeding this limit result in significantly reduced function (Wu et al., 1993). Given the requirements for 300 bp of *cis*-elements from the AAV genome (two ITR sequences at the termini) and the 4,443 bp *CFTR* coding sequence, there is little space left in the vector genome (257 bp) for a strong promoter and polyadenylation signal. Thus, the first-generation rAAV-*CFTR* vector (AV2.tgCF) that was tested in clinical trials, relied on the cryptic promoter activity of the AAV2 ITR to drive transcription of the full-length *CFTR* cDNA with a synthetic polyadenylation signal (Flotte et al., 1993; Aitken et al., 2003).

More recently, a rAAV vector, AV2.tg83-*CFTR* was developed, which uses an 83-bp synthetic promoter (tg83) (Zhang et al., 2004) to improve expression of the full-length human *CFTR* cDNA. The genome of this vector is 4.95 kb in size. Although this vector produced a 3-fold increase in cAMP-mediated Cl⁻ currents in CF HAE ALI cultures relative to AV2.tgCF, this level of expression remained suboptimal for application in CF gene therapy. Other groups have attempted to use a *CFTR* minigene

to create space for incorporating a better promoter into the rAAV vectors; this seemed justified based on earlier studies of *CFTR* gene function and structure indicating that the deletion of short, nonessential sequences from the C-terminus and regulatory domain (R-domain) had only minimal effects on the chloride channel function of *CFTR* (Zhang et al., 1998). One widely used *CFTR* minigene is *CFTR* Δ R, which lacks 156 bp encoding 52 amino acid residues (708–759) at the N-terminus of the R-domain. Gene transfer with a recombinant adenoviral vector encoding *CFTR* Δ R in CF HAE ALI cultures demonstrated that this transgene retains at least 80% of the transepithelial Cl⁻ transport supported by full-length *CFTR* (Ostedgaard et al., 2002). In addition, the expression of *CFTR* Δ R in *CFTR*^{-/-} knockout mice rescued the lethal intestinal phenotype (Ostedgaard et al., 2011). This 156 bp deletion made it possible to package a rAAV *CFTR* expression vector 4.94 kb in length, with expression driven by a minimal CMV promoter (173 bp), into an AAV5 capsid (Ostedgaard et al., 2005). Additional efforts were aimed at developing AAV variant vectors of higher apical tropism, through directed evolution of the AAV capsid in polarized HAE ALI cultures (Li et al., 2009). However, these rAAV vectors did not provide efficient *CFTR* expression because the minimal CMV promoter did not function well in fully differentiated airway epithelia.

Summary

To circumvent the size limitation of the promoter in a recombinant adeno-associated viral (rAAV) vector that can be used to express certain transgenes, a set of 100-mer synthetic enhancer elements, composed of ten 10 bp repeats, were screened for the ability to augment *CFTR* transgene expression from a short 83 bp synthetic promoter in the context of a rAAV vector for application in cystic fibrosis (CF) gene therapy. Screening for the effectiveness of synthetic enhancers to augment transgene expression was conducted in a stepwise fashion-in plasmids without AAV sequences, proviral vectors in the form of plasmids with AAV sequences, and rAAV vectors. Both plasmid transfection and viral vector transduction in cultured cell lines and whole animals *in vivo* were evaluated. Initial studies assessing transcriptional activity in monolayer (non-polarized) cultures of human airway cell lines and primary ferret airway cells revealed that three of these synthetic enhancers (F1, F5, and F10) significantly promoted transcription of a luciferase transgene in the context of plasmid transfection. Further analysis in polarized cultures of human and ferret airway epithelia at an air-liquid interface (ALI), as well as in the ferret airway *in vivo*, demonstrated that the F5 enhancer produced the highest level of transgene expression in the context of an AAV vector. Furthermore, it was demonstrated that increasing the size of the viral genome from 4.94 to 5.04 kb did not significantly affect particle yield of the vectors, but dramatically reduced the functionality of rAAV-*CFTR* vectors because of small terminal deletions that extended into the *CFTR* expression cassette of the 5.04 kb oversized genome. Since rAAV-*CFTR* vectors greater than 5 kb in size are dramatically impaired with respect to vector efficacy, a shortened ferret *CFTR* minigene with a 159 bp deletion in the R-domain was utilized to construct a rAAV vector (AV2/2.F5tg83-*CFTR* Δ R). This

vector yielded an about 17-fold increase in expression of *CFTR* and significantly improved Cl⁻ currents in CF ALI cultures. This small enhancer/promoter combination may have broad utility for rAAV-mediated gene therapy, e.g., CF gene therapy, to the airway.

5 The disclosure provides a recombinant vector such as a parvovirus vector, e.g., a recombinant adeno-associated virus (rAAV) vector or a bocavirus (BoV), such as a human BoV, vector, comprising a synthetic enhancer having a plurality of synthetic enhancer sequences operably linked to a promoter, e.g., a synthetic promoter. In one
10 embodiment, each of the plurality of enhancers has the same sequence. In one embodiment, at least 2 of the plurality of enhancers have a different sequence. In one embodiment, the synthetic enhancer is formed of different enhancer sequences, where each unique sequence may be represented once or more than once, and if more than
15 once, may be in tandem or interspersed with other (different) enhancer sequences. For example, the synthetic enhancer may have five different enhancer sequences, each represented twice in the synthetic enhancer, and the repeated sequences may be in
20 tandem (or not). In one embodiment, at least one of the enhancer sequences has a TP53 binding site. In one embodiment, at least one of the enhancer sequences has a CREB binding site. In one embodiment, at least one of the enhancer sequences has a NRF-1 binding site (CATGCGCAG). In one embodiment, plurality has a combination of
25 one or more TP53 binding sites, one or more NRF-1 binding sites, and/or one or more CREB, e.g., CREB7, binding sites. In one embodiment, the enhancer sequence has a binding site shown in one of Figures 8A-8C. In one embodiment, the plurality has 2 up to 20 distinct synthetic enhancer sequences. In one embodiment, at least one of the
30 enhancer sequences has no more than 15 bp. In one embodiment, the plurality is up to about 150 nucleotides in length, e.g., from about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, or 140 nucleotides in length. In one embodiment, the synthetic enhancer comprises F1, F5 or F10. In one embodiment, the enhancer has at least 80%, 85%, 90%, 92%, 95%, 98% or 99% nucleotide sequence identity to F1, F5 or F10. In one
35 embodiment, the linked promoter is a synthetic promoter. In one embodiment, the promoter is tg83. In one embodiment, the promoter is an AAV promoter. In one embodiment, the promoter is a heterologous promoter, e.g., from a different virus or from a mammalian genome. In one embodiment, the promoter is operably linked to an open reading frame, e.g., a heterologous open reading frame. In one embodiment, the open reading frame encodes a prophylactic or a therapeutic gene product, e.g., cystic
40 fibrosis transmembrane conductance regulator, α -antitrypsin, β -globin, γ -globin, tyrosine hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin or erythropoietin. In one embodiment, the combination of the plurality of enhancer sequences and the promoter is no more than 300 nucleotides in length, e.g., no more than 125, 150, 175, 200, 250, or 275 nucleotides in length. In one embodiment, the combination of the plurality of enhancer sequences and the promoter is less than 500
nucleotides in length. In one embodiment, the vector is a parvovirus vector such as a

rAAV vector, e.g., an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9 vector, or a human bocavirus vector, e.g., HBoV1, HBoV2, HBoV3 or HBoV4, or an evolved AAV or HBoV vector that adapts a unique tropism, e.g., optionally one with slightly altered capsid sequences from known serotypes

5 This disclosure also relates to an approach to screen tissue-specific as well as ubiquitous synthetic promoter/enhancer combinations in a step-wise fashion, in plasmids, proviral vectors, and rAAV vectors, which can be used in the application of rAAV gene therapy for the delivery of large transgene cassette. Examples of use include but are not limited to express 4.3 kb B-domain deleted Factor-VIII in muscle
10 and/or liver for hemophilia A, or to deliver the 4.2 kb the gene-editing tool of *Streptococcus pyogenes* (SpCas9) and a chimeric sgRNA together in any desired tissue and organ *in vivo*.

Further provided are methods of using the recombinant parvovirus vector to infect cells, e.g., mammalian cells such as ferret, canine, feline, bovine, equine, caprine,
15 or porcine cells, or primate cells, e.g., human cells, for example, administering a composition comprising the recombinant parvovirus vector to a mammal. For example, the recombinant parvovirus genome may include an expression cassette encoding a heterologous gene product, e.g., which is a therapeutic protein such as cystic fibrosis transmembrane conductance regulator, α -antitrypsin, β -globin, γ -globin, tyrosine
20 hydroxylase, glucocerebrosidase, aryl sulfatase A, factor VIII, dystrophin, erythropoietin, alpha 1-antitrypsin, surfactant protein SP-D, SP-A or SP-C, erythropoietin,, or a cytokine, e.g., IFN- α , IFN γ , TNF, IL-1, IL-17, or IL-6, or a prophylactic protein that is an antigen such as viral, bacterial, tumor or fungal antigen, or a neutralizing antibody or a fragment thereof that targets an epitope of an antigen such as one from a human
25 respiratory virus, e.g., influenza virus or RSV including but not limited to HBoV protein, influenza virus protein, RSV protein, or SARS protein.

Brief Description of the Figures

30 Figures 1A-1D. Effectiveness of synthetic oligonucleotide enhancers in augmenting activity of tg83-directed luciferase reporter plasmids in monolayer cultures. A) Schematic structure of the reporter vectors used to screen the enhancer library. The transcriptional motifs of the synthetic tg83 promoter are indicated. (B-D) Reporter activity in monolayer cultures of human airway cell lines (B) A549 and (C) IB3, and (D)
35 ferret primary airway cells, following transfection with the indicated plasmids. Luciferase assays were conducted 24 hours post-transfection. Data represent the mean (+/- SEM, N=3) relative luciferase activity of each transfection normalized to that of the enhancer-less vector pGL3-tg83luc, whose value in each cell-type tested was set to 1.

Figures 2A-2F. Effectiveness of enhancers F1, F5 and F10 in augmenting
40 activity of the tg83 promoter in the context of proviral plasmids and rAAV. A) Effect of the AAV2 ITR on transcription from the tg83 promoter, as evaluated following

transfection of A549 and primary airway ferret cells with pGL3-tg83 or pAV2-tg83luc. Data represent the mean ($\pm$ SEM, N=3) relative luciferase activity (RLU) 24 hours post-transfection. B) Effectiveness of enhancers on transcription following transfection of A549 and primary ferret airway cells with the indicated AAV2 proviral plasmids. Data represent the mean ($\pm$ SEM, N=3) relative luciferase activity of each transfection, normalized to the enhancer-less vector pAV2-tg83luc (set to 1 for each cell type), at 24 hours post-transfection. C) Effectiveness of enhancers on transcription following infection of A549 cells with the indicated rAAV2 vectors at 24 hours post-infection. Data represent the mean ($\pm$ SEM, N=3) relative luciferase activity for each infection, normalized to the enhancer-less vector pAV2-tg83luc (set to 1). (D and E) Effectiveness of enhancers on transcription following basolateral infection of polarized (D) human and (E) ferret airway epithelia infected with 2×10^{10} DRP of the indicated rAAV2 vectors. Data represent the mean ($\pm$ SEM, N=4) relative luciferase activity (RLU) for each condition at 2 days post-infection. (F) Effectiveness of enhancers on transcription in lung and tracheal tissue following infection of 5 day-old ferret pups with 2×10^{11} DRP of AV2/1.F5tg83luc or AV2/1.F10tg83luc, in the presence of proteasome inhibitors. Luciferase activity was measured 8 days post-infection. Data represent the mean ($\pm$ SEM, N=4) relative luciferase activity (RLU/ μ g protein).

Figures 3A-3C. Impact of rAAV-*CFTR* construct size on restoration of *CFTR* chloride currents in polarized CF airway epithelium. A) Schematic illustration of structures of rAAV2 vectors of distinct sizes that encode the full-length ferret *CFTR* open reading frame (ORF) and R domain-deleted variants, under the control of the same transcriptional elements: the 83 bp synthetic promoter (tg83), a 62 bp synthetic polyadenylation signal (pA), a 17 bp 5' untranslated region (UTR), and a 9 bp 3' UTR. The ORF of full-length ferret *CFTR* (*fCFTR*) is 4455 bp. The 99 bp 3xHA tag was inserted between amino acid residues S900 and I901, bringing *fCFTR*(HA) to 4554 bp. The *fCFTR* Δ R has a shortened ORF (4,296 bp); 53 amino acid residues (I708–I760, 159 bp) are deleted from the R-domain. *fCFTR* Δ R(HA) is 4395 bp in length, having a 99 bp HA-tag insertion and a 159 bp deletion in the R-domain. The functionalities of these vectors on rescue of *CFTR* specific Cl^- transport (reflecting by transepithelial short-circuit currents (Isc)) were compared in differentiated CF HAE ALI cultures, following infection at 10^{11} DRP per Millicell insert (MOI of about 10^5 DRP/cell) in the presence of the proteasome inhibitors LLnL (10 μ M) and doxorubicin (2 μ M). CF HAE ALI cultures were generated from a conditionally transformed human CF airway cell line (CuFi8; genotype Δ F508/ Δ F508). B) Typical traces of the Isc changes from CF ALI cultures, infected indicated AAV-*CFTR* vectors, following the sequential addition of various inhibitors and agonists. Amiloride and DIDS were used to block ENaC-mediated sodium currents and non-*CFTR* chloride channels prior to addition of cAMP agonist (forskolin and IBMX), and GlyH101 was used to block *CFTR*-specific currents. Δ Isc (IBMX & Forsk) reflects the activation of *CFTR*-mediated chloride currents following induction with cAMP agonist, and Δ Isc (GlyH101) reflects the inhibition of *CFTR*-mediated

chloride currents following addition of GlyH101. C) Effects of vector size on rescue of chloride Isc currents. rAAV-*CFTR* vectors were increased by about 100 bp increments. Shown are the Δ Isc (IBMX & Forsk) and Δ Isc (GlyH101) responses, indicating the magnitude of *CFTR*-mediated chloride transport following basolateral infection CF HAE ALI, as described in (B). *CFTR* currents generated from primary non-CF HAE (N=14) are provided for comparison. Data represent the mean ($\pm$ SEM) for N=3 independent Millicell inserts.

Figures 4A-4B. Analyses of integrity of the viral genome by denaturing gel electrophoresis and slot blot analysis. A) Viral DNA was extracted from 10^9 DRP of the indicated AAV-*CFTR* vectors, resolved on a 0.9% alkaline agarose gel, and transferred to a Nylon membrane. Southern blotting was performed with a 32 P-labeled *CFTR* probe to visualize the viral DNA. B) To assess potential deletion that may have occurred at the termini of positive and minus strand viral genomes, 3.33×10^8 DRP of each virus (titer determined by TaqMan PCR with probe/primer set against f*CFTR* cDNA) were loaded in triplicate onto a Slot-Dot® SF Module (Bio-Rad, Hercules, CA) fitted with a Nylon membrane. 3-fold serial dilution of proviral plasmid (3×10^9 to 3.7×10^7 copies) was also loaded for generating the standard curves for quantitation. The blots were probed with 32 P-labeled oligonucleotides against the tg83 promoter, *CFTR* cDNA, or polyA. (-) and (+) represent the probes hybridizing to the minus and positive strand of the single stranded rAAV genome. Hybridization was first conducted with the set of probes that hybridize to the minus strand, and then re-probed with the set of oligonucleotides that hybridize to the positive strand. The number of viral genome copies detected by each probe was determined (mean $\pm$ S.E.M, N=3) based on measurement of the signal density using NIH ImageJ and comparison to standard curves.

Figure 5. Effects of the F5 enhancer on *CFTR* currents generated by CF HAE following infection with rAAV vectors. CF HAE ALI were infected with AV2/2.tg83-f*CFTR* Δ R or AV2/2.F5tg83-f*CFTR* Δ R, at the indicated MOIs, from the apical or basolateral surface. Proteasome inhibitors were co-administrated during the 16 hours infection period. Isc measurements of the infected ALI cultures were conducted at 2 weeks post-infection. The mean ($\pm$ SEM) Δ Isc (IBMX & Forsk) and Δ Isc (GlyH101) are shown with the N for independent transwells assays indicated. Mock-infected CF and non-CF HAE cultures are shown for reference.

Figures 6A-6B. Effects of the F5 enhancer on *CFTR* currents and tg83-directed *CFTR* transcription following infection with rAAV vectors. CF HAE ALI were infected with AV2/2.tg83-f*CFTR* Δ R or AV2/2.F5tg83-f*CFTR* Δ R at an MOI of 2×10^4 DRP/cell from the basolateral surface, in the presence of proteasome inhibitors. A) Isc was measured in the infected ALI cultures at 3 and 10 days post-infection. Δ Isc (IBMX & Forsk) and Δ Isc (GlyH101) values are presented. B) The abundance of vector-derived *CFTR* mRNAs in cultures evaluated in Panel a, as determined using RS-PCR and normalized to GAPDH transcripts in each sample. Data represent the mean ($\pm$ SEM) for N=3 independent transwells in each panel.

Figures 7A-7B. 5 day old ferrets were systemically infected with 2×10^{11} DRP AAV2/9F5tg83luc or AAV2/9F10tg83luc via jugular vein injection. Animals were euthanized 8 day post-infection, snap tissues from different organs were harvested and homogenized in reporter lysis buffer (Promega) for luciferase assays. A) Data compare the luciferase expression from the infections of AAV2/9F5tg83luc or AAV2/9F10tg83luc when the luciferase expression from F5tg83 promoter was arbitrarily set as 100 in each tissue. B) Values represent the (mean $\pm$ SEM, n=3) relative luciferase activity (RLU/ μ g protein).

Figures 8A-8W. A-E) Binding sites in F5 which may be employed to prepare synthetic enhancers as described herein. F-P) Binding sites in F10 which may be employed to prepare synthetic enhancers as described herein. Q-W) Binding sites in F5tg83, which may be employed to prepare synthetic enhancers or promoter as described herein. SEQ ID NOs: 31-68.

Figures 9A-D. Gene transfer efficiency of AV.F5Tg83-hCFTR Δ R to the ferret trachea and lung. Three day old ferrets were infected with a 100 μ L volume of 6×10^{11} DRP of AV.F5Tg83-hCFTR Δ R in 500 μ M doxorubicin. Non-infected animals were given an equal volume of vehicle with doxorubicin. At 10 days post-infections the entire lung and trachea were harvested and snap frozen in liquid nitrogen. Tissue was pulverized and mRNA and cDNA generated for Q-PCR of human and ferret CFTR. (A and B) Copies of hCFTR and fCFTR mRNA in the (A) trachea and (B) lung. Copy number was determined using a standard curve generated from serial dilutions of plasmid CFTR cDNA for each species. (C and D) Ratio of transgene-derived hCFTR to endogenous fCFTR mRNA. C1-C3 represent animals in the mock-infected group and A1-A3 represent animals in the AAV-infected group. The average is also shown for the three AAV-infected animals. The dashed line represents endogenous levels of CFTR (ratio = 1). Data depicts the mean $\pm$ SEM for N=3 animals in each group.

Figures 10A-D. AV.F5Tg83-hCFTR Δ R effectively transduces the mature ferret airways. The lungs of 1 month old ferrets (N=3) were transduced with 7.5×10^{12} DRP of AV.F5Tg83-hCFTR Δ R harboring the hCFTR Δ R cDNA in a 500 μ L volume of PBS in the presence of 250 μ M doxorubicin. A mock-infected control animal (N=1) received 500 μ L PBS with no vector in the presence of 250 μ M doxorubicin. Vector was delivered to the lung with a PennCentury microsyringer through tracheal intubation. Nasal delivery in the same animals was also performed using 100 μ L containing 1.5×10^{12} DRP with 250 μ M doxorubicin by instillation of fluid. Mock-infected nasal delivery received PBS with 250 μ M doxorubicin. At 12 days following infection, the lung lobes were harvested separately along with the trachea, carina, and nasal turbinates with surrounding adventitia. The tissues were snap frozen and pulverized samples were processed separately for mRNA and DNA. A) TaqMan RNA-specific PCR (RS-PCR) for human CFTR mRNA and endogenous ferret GAPDH mRNA for vector and mock treated animals. Results show the ratio of hCFTR/fGAPDH mRNA. B) TaqMan RS-PCR for

endogenous ferret CFTR mRNA and endogenous ferret GAPDH mRNA for vector and mock treated animals. Results show the ratio of fCFTR/fGAPDH mRNA. C) TaqMan Q-PCR for the number vector genomes in each sample per 100 ng DNA. D) The ratio of mRNA copies for hCFTR/fCFTR for each sample. 1 is equal to endogenous levels of CFTR (red dashed line). Lung samples contained on average 3.0+/-0.5 copies of transgene derived hCFTR mRNA per copy of fCFTR mRNA. Trachea and nasal tissue transduction was more variable, but averaged one copy of transgene derived hCFTR/fCFTR mRNA. Results depict the mean +/-SEM for the vector treated animals.

Detailed Description

Gene therapy has been widely used in clinical trials since 1990s with many successful cases reported using viral or non-viral vectors to deliver therapeutic genes. rAAV is the most widely used one proven of high safety profile, broad tissue/organ tropism and persistence transgene expression. AAV is a small single stranded DNA virus of an inherently small 4.679 kb genome, thus the application of rAAV for gene therapy is restricted to delivering relative small transgenes. Although AAV capsid can house a rAAV genome slightly larger than its original size, 4.95 kb appears to be the maximal size for efficient transgene expression. Since a 300-bp sequence of an AAV essential *cis* element (terminal repeats at both termini) is included in a rAAV vector, the actual insertion of an exogenous gene expression cassette cannot exceed 4.6 kb. This is a challenge for delivering effective expression of a large gene whose size approaches to this limit.

One typical example is to deliver the *CFTR* gene (cystic fibrosis transmembrane conductance regulator) for cystic fibrosis (CF) gene therapy using rAAV vector. The coding sequence for *CFTR* gene is as large as 4.443 kb. To construct a CFTR expressing AAV vector, with the necessity of minimal 5' and 3' UTR and the cloning sites, there is a room of less than 200 bp to incorporate promoter and polyadenylation signal to direct the transcription of full-length *CFTR* cDNA.

Recently, a *CFTR* knockout ferret model was established that spontaneously develops a lung phenotype that mirrors key features of human CF disease, including spontaneous bacterial infection of the lung, defective secretion from submucosal glands, diabetes, and gastrointestinal disease (Sun et al., 2008; Sun et al., 2010; Oliver et al., 2012; Sun et al., 2014; Yan et al., 2013). It has been demonstrated that the airways of newborn ferrets can be efficiently transduced by rAAV1 in the presence of proteasome inhibitors (Yan et al., 2013). Thus, preclinical studies in the CF ferret model can be initiated as soon as a rAAV vector that effectively expresses *CFTR* in airway epithelium is generated. rAAV inherently small 4.679 kb genome necessitates the use of a short but robust transcription regulatory element to effectively express a large transgene whose size approaches to the package limit. cassette was generated that efficiently expresses the ferret *CFTR* (fCFTR) gene.

The first-generation rAAV-*CFTR* vector (AV2.tgCF), relied on the cryptic promoter activity of the AAV2 ITR, inefficiently expressed *CFTR* in clinical trials. To

overcome this problem, another rAAV vector, AV2.tg83-*CFTR*, which uses an 83-bp synthetic promoter (tg83) was used to improve expression. Although this vector produced a 3-fold higher in cAMP-mediated Cl⁻ currents in CF HAE ALI cultures than AV2.tgCF, this level of expression remains suboptimal for application in CF gene therapy. So, there is an immediate need for a strong short promoter to direct the *CFTR* expression in the AAV vector for CF gene therapy. Similarly, to express the 4.3kb B-domain deleted Factor-VIII in muscle and/or liver for hemophilia gene therapy using rAAV, short promoter effective in muscle and liver is also needed.

Another example is to deliver the CRISPR/Cas9 system for gene editing. The recent development of CRISPR/Cas9 gene editing technique promotes a new human gene therapy strategy by correcting a defect gene at pre-chosen sites without altering the endogenous regulation of gene of interest. This system consists of two key components: Cas9 protein and sgRNA, as well as a correction template when needed. rAAV can be used to deliver these elements *in vivo* to various target organs, but the co-delivery of Cas9 protein and the a chimeric sgRNA in the same cell is required while the dual-AAV vector delivery system is low efficient. Because the size of the expression cassette for *Streptococcus pyogenes* (SpCas9) and the transcription cassette sgRNA together exceeds 4.2 kb, to use a single rAAV vector to deliver the efficient expression SpCas9 protein, it necessitates the use of small but robust promoter/enhance sequence to direct the SpCas9 expression, thus, ubiquitous and/or tissue-specific enhancers are desired. Although *Staphylococcus aureus* Cas9 (SaCas9), which is about 1.0 kb smaller in size, fits together with its sgRNA and relevant expression cassettes within a single AAV vector, using short synthetic promoter allows for the additional incorporation of the gene correction template for an all-in-one rAAV vector in the application of gene editing-based gene therapy.

As described below, short (less than 0.2 kb) synthetic enhancer/promoters provide a solution to solve the current problem of rAAV vector in delivering a large transgene cassette. This disclosure, in one embodiment, relates to the use of a 183-bp F5tg83 synthetic enhancer/promoter to rAAV vectors to deliver effective *CFTR* expression in lung airway tissue for CF gene therapy. This disclosure, in one embodiment, also provides an effective approach to screen and identify tissue-specific or ubiquitous synthetic promoter/enhancer combinations.

Since enhancer activity differs by cell lines and state of cell differentiation, as well as is influenced by the AAV ITRs and by the sequence of gene of interest, the screening was conducted in a step-wise fashion, e.g., in plasmids, proviral vectors, and rAAV vectors.

In one embodiment, the screening system includes a defined 83-mer synthetic core promoter (tg83p) and a set of random 100-mer synthetic sequence of potent enhancer activity. The screening approach can be used to screen the 100-mer synthetic sequences for their enhancer activity to enhance promoter transcription, e.g., the 83 bp tg83p promoter transcription, in different organ/tissue for different gene of

interests, in a similar in a step-wise fashion: such as to direct the Factor VIII expression in muscle or liver, as well as to direct the Cas9 protein expression in any specific tissues or stem cells. Besides tissue-specific expression, the approach also can be used to identify an enhancer of ubiquitous effect to improve the tg83p promoter activity in a wide range of tissue/organ, through testing rAAV derived reporter gene expressions at a multi-organ level.

Specifically, a set of vectors containing the synthetic tg83 promoter linked with different synthetic sequences (about 100 bp) of potent enhancer activity, was constructed for initial screening in monolayer (non-polarized) cultures of human airway cell lines and primary ferret airway cells, which as discussed below revealed that three of these synthetic enhancers (F1, F5, and F10) significantly promoted transcription of a luciferase transgene from tg83p in the context of plasmid transfection. The next was to construct rAAV reporter vectors with pre-chosen candidates (F1-, F5-, or F5- tg83p enhancer/promoter combination). These vectors also incorporated a partial sequence of the gene of interest (*CFTR* here) that can maximally fit into the rAAV genome; this approach allows for the screening of cDNA sequences that will ultimately reside in the recombinant virus and also influences enhancer/promoter activity through unknown processes (likely secondary structure of the DNA). Analysis in polarized cultures of human and ferret airway epithelia at an air-liquid interface (ALI) in the context of AAV vector infection found that the combination of F5tg83 (183 bp in length) was the most efficient promoter in both ALI cultures, leading to 19.6-fold and 57.5-fold increases in reporter (firefly luciferase) expression, respectively, over the enhancer-less counterpart. The F5tg83 promoter also produced the highest level of transgene expression in the ferret airway *in vivo*. Finally, the F5tg83 promoter was used the rAAV-*CFTR* vector to direct the *CFTR* expression, the vector (AV.F5tg83*CFTR* Δ R) yielded an about 17-fold increase related to the enhancer-less vector (AV.tg83*CFTR*R) in vector derived *CFTR* mRNA transcription and significantly improved Cl⁻ currents in human CF ALI cultures.

Thus, expression from rAAV vectors having a large transgene was enhanced using small synthetic enhancer/promoter combinations having from a defined 83-mer synthetic core promoter and a set of random synthetic 100-mer synthetic enhancers. In particular, several short 183 bp synthetic promoter/enhancer combinations (F5tg83, F1tg83 and F10tg83) were capable to direct strong transgene expression in human as well as non-human mammalian (such as ferret) airway cells. In one embodiment, the robust F5tg83 promoter can be used in rAAV vector to deliver the 4.4 kb cystic fibrosis transmembrane conductance regulator (*CFTR*) for cystic fibrosis gene therapy.

The invention will be further described by the following non-limiting examples.

Example 1

Materials and Methods

Production of rAAV Vectors. All rAAV vector stocks were generated in HEK293 cells by triple plasmid co-transfection using an adenovirus-free system, and purified

with two rounds of CsCl ultracentrifugation as reported in Yan et al. (2004). For all viral vectors and proviral plasmids, rAAV2 genomes were used and packaged into AAV2 or AAV1 capsid to generate rAAV2/2 and rAAV2/1 viruses, respectively. TaqMan real-time PCR was used to quantify the physical titer (DNase resistant particles, DRP) of the purified viral stocks as described in Yan et al. (2006) and Ding et al. (2006). The PCR primer/probe set used to titer luciferase vectors was: 5'-TTTTTGAAGCGAAGGTTGTGG-3' (forward primer) (SEQ ID NO:1), 5'-CACACACAGTTCGCCTCTTTG-3' (reverse primer) (SEQ ID NO:2) and 5'-FAM-ATCTGGATACCGGGAAAACGCTGGGCGTTAAT-TAMRA-3' probe) (SEQ ID NO:3); the primer/probe set used for ferret *CFTR* vectors was 5'-GACGATGTTGAAAGCATACCAC-3' (forward primer) (SEQ ID NO:4), 5'-CACAACCAAAGAAATAGCCACC -3' (reverse primer) (SEQ ID NO:5) and 5'-FAM-AGTGACAACATGGAACACATACCTCCG -TAMRA-3' (probe) (SEQ ID NO:6). All primers and probes were synthesized by IDT (Coralville, IA). The PCR reaction was performed and analyzed using a Bio-Rad My IQ™ Real-time PCR detection system and software.

Analysis of Integrity of Viral Genomes. Viral DNA was extracted from 10⁹ DRP of AAV-*CFTR* vectors and resolved in 0.9% alkaline denatured agarose gel at 20 volts overnight in 50mM NaOH/1 mM EDTA buffer. Following transfer to a Nylon membrane, Southern blotting was performed with a ³²P-labeled *CFTR* probe to visualize the viral DNA. For examination of 5' end genome deletions in the oversized rAAV vectors, 3.33x10⁸ DRP of each virus (quantitated by TaqMan PCR with probe/primer set against *CFTR* cDNA) was loaded into a slot blotting Nylon membrane. The blots were first hybridized to a set of three ³²P-labeled oligonucleotide probes against the minus strand of the rAAV genome: at the 5' sequence of the tg83 promoter: taccctcgagaacggtgacgtg (SEQ ID NO:7); the center of ferret *CFTR* cDNA: ggagatgcgctgtctctggaatg (SEQ ID NO:8); and the 3' sequence of the synthetic polyA: gcatcgatcagagtgtgtgtttttgtgtg (SEQ ID NO:9). After exposure to X-film, the membranes were stripped of probe and hybridized again to another set of three ³²P-labeled oligonucleotide probes complimentary to the positive strand. NIH ImageJ software was used to quantify the signal intensity of hybridization to determine the corresponding number of genomes detected by each probe with serial dilutions of the proviral plasmid as standards.

Cell Culture and Conditions for Transfections and Infections. Human airway cell lines A549 and IB3, as well as HEK 293 cells, were cultured as monolayers in Dulbecco's modified Eagle medium (DMEM), supplemented with 10% fetal bovine serum and penicillin-streptomycin, and maintained in a 37°C incubator at 5% CO₂. Primary ferret airway cells were isolated and cultured as non-polarized monolayer or at an ALI to generate polarized epithelia as described in Liu et al. (2007). Polarized primary HAE were generated from lung transplant airway tissue as described in Karp et al. (2002) by the Cells and Tissue Core of The Center for Gene Therapy at the University of Iowa. Polarization of cells of the CuFi8 line, a conditionally transformed cell

line that was generated from $\Delta F508/\Delta F508$ CF airway cells (Zabner et al., 2003), were polarized at an ALI using conditions similar to those used for primary HAE (Yan et al., 2013). Ferret and human airway epithelia were grown on 12 mm Millicell membrane inserts (Millipore) and differentiated with USG medium of 2% Ultrosor G supplement (Pall BioSeptra, SA, France) at an ALI prior to use. Cell lines and primary monolayer cultures of airway cells were transfected with plasmids using lipofectamine and 1.0 μ g of plasmid. For rAAV infections of A549 cells, polarized human or ferret airway epithelial cells, vectors were typically left in the culture medium for 24 hours (A549 cells) or 16 hours (polarized cells). For apical infection of the polarized HAE ALI cultures, vectors were diluted in USG medium to a final volume of 50 μ L and applied to the upper chamber of the Millicell insert. For basolateral infections, vectors were directly added to the culture medium in the bottom chamber. Proteasome inhibitors were supplied in the culture medium throughout the period of infection to polarized cells, at 40 μ M LLnL (N-Acetyl-L-leucine-L-leucine-L-norleucine) and 5 μ M doxorubicin in the case of polarized human, and 10 μ M LLnL and 2 μ M doxorubicin in the case of CuFI ALI cultures and ferret ALI cultures. Epithelia were exposed to the viruses and chemicals for 16 hours and then removed. At this time, the Millicell inserts were briefly washed with a small amount USG medium and fresh USG medium was added to the bottom chamber only. Doxorubicin was from Sigma (St, Louis, MO) and LLnL was from Boston Biochem (Cambridge, MA).

rAAV Infection of Ferret Lungs. All animal experimentation was performed according to protocols approved by the Institutional Animal Care and Use Committee of the University of Iowa. *In vivo* infection of ferret lungs was performed by intra-tracheal injection of a 300 μ L inoculum containing 2×10^{11} DRP of rAAV2/1 and 250 μ M doxorubicin. Prior to infection at 5 days of age, ferret kits were anesthetized by inhalation of a mixture of isoflurane and oxygen. At 8-day post-infection, the animals were euthanized with an overdose sodium pentobarbital intraperitoneal injection. For luciferase expression assays, the ferret trachea and lung cassette was immediately frozen in liquid nitrogen and then pulverized using a cryogenic tissue pulverizer. 1 ml of Passive Lysis Buffer (Promega, Madison, WI) was added to the pulverized tissue to extract protein. After four freeze-thaw cycles, the tissue extract was centrifuged at 15,000 rpm for 5 minutes, and the clarified tissue extract was used for luciferase assays with a luciferase assay kit from Promega.

Measurement of Expression of the Firefly Luciferase Reporter. At the indicated times post-infection or transfection, cells were lysed with luciferase cell lysis buffer and luciferase enzyme activity in cell lysates was determined using the Luciferase Assay System (Promega) in a 20/20 luminometer equipped with an automatic injector (Turner Biosystems, Sunnyvale, CA).

Measurement of Short-Circuit Currents. Transepithelial short circuit currents (Isc) were measured using an epithelial voltage clamp (Model EC-825) and a self-

contained Ussing chamber system (both purchased from Warner Instruments, Inc., Hamden, CT) as described in Liu et al. (2007). Throughout the experiment the chamber was kept at 37°C, and the chamber solution was aerated. The basolateral side of the chamber was filled with buffered Ringer's solution containing 135 mM NaCl, 1.2 mM CaCl₂, 1.2 mM MgCl₂, 2.4 mM KH₂PO₄, 0.2 mM K₂HPO₄, and 5 mM Hepes, pH 7.4. The apical side of the chamber was filled with a low-chloride Ringer's solution in which 135 mM Na-gluconate was substituted for NaCl. Transepithelial voltage was clamped at zero, with current pulses applied every 5 seconds and the short-circuit current recorded using a VCC MC8 multichannel voltage/current clamp (Physiologic Instruments) with Quick DataAcq software. The following chemicals were sequentially added to the apical chamber: (1) amiloride (100 μM), to inhibit epithelial sodium conductance by ENaC; (2) 4,4'-diisothiocyanato-stilbene-2,2'-disulfonic acid (DIDS) (100 μM), to inhibit non-*CFTR* chloride channels; (3) the cAMP agonists forskolin (10 μM) and 3-isobutyl-1-methylxanthine (IBMX) (100 μM) to activate *CFTR* chloride channels; and (4) the *CFTR* inhibitor GlyH-101 (N-(2-naphthalenyl)-[(3,5-dibromo-2,4-dihydroxyphenyl) methylene] glycine hydrazide) (10 μM) to block Cl⁻ secretion through *CFTR*. ΔI_{sc} was calculated by taking the difference of the plateau measurement average over 45 seconds before and after each change in conditions (chemical stimulus).

Quantitative Analysis of Vector-Derived *CFTR* mRNA Following Transduction with rAAV. The total RNA from rAAV-infected cells was prepared using the RNeasy Mini plus Kit (Qiagen). Since the residual ssDNA rAAV genome in the RNA sample can be an undesirable template for traditional Real Time PCR, a modified RNA-specific method for PCR of the rAAV vector⁴⁶ was used to detect the vector-derived ferret *CFTR* mRNA. In brief, the 1st-strand cDNA synthesis was primed with an adapter (lower case)-linked, vector-specific primer that targets the synthetic polyadenylation signal sequence (upper cases). The sequence of this primer is 5'-gcacgagggcgacugucaUGAUCGAUGCAUCUGAGCUCUUUAUUA-3' (SEQ ID NO:10), in which all dTs are replaced with dU. After RNase H digestion was carried out to eliminate the RNA templates, a ferret *CFTR*-specific primer (5'-TGCAGATGAGGTTGGACTCA-3'; SEQ ID NO:11) was used for synthesis of the 2nd strand. In order to avoid false amplification from cDNA produced from the single-stranded viral DNA, all of the dU components in the 1st- and 2nd-strand cDNA products, as well as the excess adapter primers, were degraded by applying uracyl-N-glycosylase (UNG). Thus, a 2nd-strand cDNA product linked to the complementary sequence of the adapter derived exclusively from rAAV transcripts was produced. The primer set for TaqMan PCR contained the ferret *CFTR* sequence 5'-CAAGTCTCGCTCTCAAATTGC-3' (SEQ ID NO:12), and the adapter sequence 5'-GCACGAGGGCGACTGTCA-3' (SEQ ID NO:13). The TaqMan probe used was 5'-FAM-ACCTCTTCTTCCGTCTCCTCCTTCA-TAMRA-3' (SEQ ID NO:14).

40 Results

Synthetic oligonucleotide enhancers that increase tg83 promoter-driven transcription in airway cells.

A previous unbiased screen evaluating short synthetic enhancers from a library containing 52,429 unique sequence identified enhancer elements capable of activating transcription from the 128 bp minimal cytomegalovirus (CMV) IE promoter (-53 to +75) in HeLa cells (Schlabach et al., 2010). This library comprised all possible 10-mer DNA sequences, printed on microarrays as 10 tandem repeats (for a total length of 100 bases each). The best-performing 100-mer oligonucleotides enhanced the transcription of this 128 bp CMV IE minimal promoter to 75%–137% of that induced by the 600 bp wild type CMV IE promoter (Schlabach et al., 2010). In previous studies, a 83 bp synthetic promoter sequence (tg83) was used to express the full-length CFTR gene from a rAAV vector (AV2.tg83-*CFTR*), and it was found to produce higher transgene expression in CF HAE cultures than the cryptic promoter of the AAV2 ITR (Zhang et al., 2009). The tg83 promoter consists of an ATF-1/CREB site and an Sp1-binding site from the promoter of the Na,K-ATPase α 1 subunit, and the TATA box and transcription start site from the CMV IE promoter. It was hypothesized that combining the tg83 promoter with a synthetic enhancer identified through this library screen would produce transcriptional units of greater efficiency in polarized human and/or ferret airway epithelia *in vitro* and *in vivo*. To test this possibility, the top eight enhancer sequences identified by Schlabach et al. (F1, F4, F5, F10, C9, D3, CREB6 and CREB8; Schlabach et al., 2010) were evaluated for their ability to enhance tg83 transcription in human and ferret airway epithelium.

F1

AGTCAGGGCAAGTCAGTGGCAAGTCAGGGCAGTCAGGGCAGTCAGGGCAAGTC
AGGGCAAGTCAGGGCAAGTCAGGGCAAGTCAGGGCAAGTCAGGGCA (SEQ ID
NO:15)

F10

gaattgacgcatatattgacgcatattgacgcaaattgacgcaaattgacagcaagattgacgcaaattgagcgcaaatt
gacgcaaattaattgacgcat (SEQ ID NO:16)

F4

CTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGAGC
AATCTGATGCAATCTGATGCAATATGATGAATGTGATGCAAT (SEQ ID NO:17)

F5

TGGTGAGCGTCTGGGCATGTCTGGGCATGTCTGGGCATGTCTGGGCATGTCTCGGG
CATTCTGGGCGTCTGGGCATGTCTGGGCATGTCTGGGCA (SEQ ID NO:18)

C3

GCTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGAG
CAATCTGATGCAATCTGATGCAATATGATGAATGTGATGCAATT (SEQ ID NO:19)

D9

GCTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGATGCAATCTGAG
CAATCTGATGCAATCTGATGCAATATGATGAATGTGATGCAATT (SEQ ID NO:20)

ATTGACGCGGATTGACGCGGATTGACGCGGATTGACGCGGATTGACGCGGATTG
ACGCGGctcgagaacggtgacgtgcacgcgtggcgaggccatcacgcaggttgctataagcagagctcgtt
agtgaaccgtcaga (SEQ ID NO:30)

- The tg83 promoter was cloned into the promoter-less luciferase reporter
5 plasmid pGL3-Basic Vector (Promega) to generate pGL3-tg83. Next a series of
luciferase reporter expression plasmids were constructed, in which one of the eight 100-
mer enhancers was placed in front of the tg83 promoter of pGL3-tg83 (Figure 1A).
Comparison of reporter expression from pGL3-tg83 and its enhancer-containing
derivatives was conducted in monolayer (non-polarized) cultures of two human airway
10 cell lines (A549 and IB3) and primary ferret airway cells (Figures 1B-1D). Two additional
luciferase expression plasmids, pAV2-CMV-luc (contains the wild type, 600 bp CMV IE
enhancer-promoter) and pAV2-CBA-luc (contains the CMV IE enhancer-chicken β -actin
promoter, i.e., the CBA promoter) were included as controls for high-level promoter
activity. Assessment of luciferase expression following plasmid transfection
15 demonstrated that all of the enhancers tested increased tg83-driven luciferase
expression, and that their efficiencies varied by cell line: in the human A459 cell and the
primary ferret airway cell cultures, F1tg83 and F5tg83 exceeded the activity of the CBA
and CMV promoters; and in the human IB3 cell cultures, F10tg83 was most effective but
drove far less expression than the CMV promoter (Figures 1B-1D).
20 The F5 element most efficiently enhances tg83-driven transcription in polarized human
and ferret airway epithelia *in vitro*, as well as in the ferret airway *in vivo*.

Since the F1, F5 and F10 enhancers were the most effective in activating tg83-
driven transcription in airway-cell monolayer cultures, the abilities of these elements to
promote transcription in the context of rAAV vector genomes was evaluated. Four rAAV
25 proviral vectors harboring a luciferase expression cassette were constructed, with
expression driven by tg83 (enhancer-less), F1tg83, F5tg83 or F10tg83. The pAV2-tg83-
fCFTR proviral plasmid was used as the template vector for cloning, its promoter and
the 5' portion of the fCFTR coding region were replaced with the 2.1 or 2.2 kb luciferase
expression cassette. The genome size was 4.75 kb in the case of rAV2.tg83luc, and
30 4.85 kb for the enhancer-containing vectors. This design was used for two reasons.
First, retaining as much of the fCFTR sequence as possible ensured that the vector
genome size would be similar to those of the rAAV-CFTR expression vectors that would
ultimately be generated. Second, retaining regions of the fCFTR cDNA maximized the
potential influences of the ferret CFTR sequence on enhancer function.

35 As a first step in investigating whether AAV ITRs and the portion of fCFTR
transgene sequence to be tested (i.e., 3' half of the fCFTR cDNA) influence transcription
from the tg83 promoter, reporter expression from pGL3-tg83 and pAV2-tg83luc
plasmids was compared following transfection into monolayer cultures of A549 and
primary ferret airway cells. pAV2-tg83luc plasmid was found to be 2.5-fold (in A549) and
40 2-fold (in primary ferret airway cells) more transcriptionally active than the pGL3-based
plasmids (Figure 2A), suggesting that inclusion of the AAV ITR and/or the fCFTR stuffer

sequences had an overall positive effects on activity of the tg83 promoter. Then reporter-gene expression for pAV2-F1tg83luc, pAV2-F5tg83luc, pAV2-F10tg83luc, and pAV-tg83luc plasmids was compared. As expected, the F1, F5 and F10 enhancers significantly improved transcription from the tg83 promoter (about 10- to 19-fold) in both cell types (Figure 2B). However, the effectiveness of nearly all enhancers was significantly reduced (about 3- to 18-fold) within the rAAV proviral plasmids when compared to pGL3-tg83 plasmids lacking ITRs and the *CFTR* sequence (Figure 2B solid bars vs. Figure 1B; Figure 2B open bars vs Figure 1D). This suggests that the sequences from the AAV ITR and/or portions of the ferret *CFTR* cDNA have an overall negative impact on enhancer function. However, this effect on the synthetic enhancers differed between the A549- and ferret primary airway-cell monolayers. In A549 cells, the F1 enhancer was most significantly influenced, with its activity in the rAAV proviral plasmid decreased by 18.1-fold, whereas those of the F5 and F10 enhancers decreased by only 8.2-fold and 3.8-fold, respectively. In primary ferret airway cells, the F1 and F5 enhancers had 4.4-fold and 2.8-fold decreased activity, respectively, in the context of the proviral plasmid, whereas the function of F10 was slightly enhanced (about 40%).

Next expression from the various enhancer elements was evaluated in the context of rAAV2/2 vectors. In A549 cells, similar increases in expressions from the enhancer/tg83 promoter combination were observed following the transfection with the proviral plasmid and infection with the corresponding rAAV vector (Figure 2B solid bars vs. Figure 2C). Primary human and ferret airway epithelial ALI culture were then infected with equal titers of each rAAV vector, and transgene expression was assessed at 2 days post-infection. These experiments demonstrated that F5tg83 is the most efficient promoter in both human and ferret ALI cultures (Figures 2D and 2E), leading to 19.6-fold and 57.5-fold increases, respectively, in tg83-driven transcription over that driven by the enhancer-less control (Figures 2D and 2E). Notably, the differentiated state of ferret airway epithelial cells appeared to dramatically influence expression from the various enhancer/tg83 promoter combinations in the context of rAAV transduction; the F5 enhancer more effectively enhanced tg83 expression in the polarized epithelium (Figure 2E; 57.5-fold) than in undifferentiated monolayers (Figure 2B; 16.6-fold); the F1 enhancer only marginally increased activity of the tg83 promoter in polarized cells, but increased transgene expression 13.8-fold in monolayer cells.

Lastly, the *in vivo* activities of the F5tg83 and F10tg83 promoters were compared in the airways of newborn ferrets, using intratracheal injection of two rAAV1 capsid pseudotyped vectors (AV2/1.F5tg83luc and AV2/1.F10tg83luc; equal particle titers injected). This capsid serotype had previously been shown to be effective at transducing the ferret airways in the presence of a proteasome inhibitor (Yan et al., 2013). Luciferase activity was measured in extracts prepared from tracheal and lung tissue at 8-day post-infection, and F5tg83 was found to be more effective than F10tg3 in

transducing both ferret lung and trachea (Figure 2F). These findings were consistent with those for polarized ferret airway epithelial ALI cultures (Figure 2E).

A narrow limit for rAAV genome size significantly influences functionality of rAAV-*CFTR* vectors while not altering packaging efficiency.

5 The size of the expected AV.tg83f*CFTR* genome if fully packaged is 4.937 kb (Figure 3A). Incorporation of the F5 enhancer would increase this to 5.040 kb. Although it is well accepted that AAV can encapsidate a rAAV genome slightly longer than its natural size (4.679 kb), gradually increasing the size of a rAAV vector from 4.675 kb to 4.883 kb and 5.083 kb results in 25% and 75%, respectively, decreases in transduction
10 (Dong et al., 1996). Furthermore, single-molecule sequencing (SMS) of the two rAAV termini following packaging of a 5.8 kb proviral genome revealed that the 5' ITR was unstable and had incurred deletions (Kapranov et al., 2012). Given that the limits for functional genome packaging in the context of rAAV-*CFTR* vectors have yet to be defined, it was uncertain whether a 5.04 kb AV.F5tg83f*CFTR* genome would be
15 compromised with respect to genome stability and function.

 This question was addressed by constructing a 5.036 kb AV2.tg83-f*CFTR*(HA) vector in which the *CFTR* expression cassette was expanded by the addition of a 3xHA epitope tag (99 nucleotides) in the region encoding the fourth extracellular loop (ECL4) of ferret *CFTR* (previous studies had revealed that this insertion has no impact on
20 chloride-channel function (Glozman et al., 2009; Fisher et al., 2012)). This vector allowed us to interrogate how size of the genome influences *CFTR* functionality in the absence of changes to transcription of the transgene. Two rAAV2 vectors were produced (AV2/2.tg83-f*CFTR* and AV2/2.tg83-f*CFTR*-HA; Figure 3A), and their ability to generate *CFTR*-mediated chloride currents was evaluated in polarized CF HAE. Vector
25 yields for the two viruses were nearly equivalent (AV2/2.tg83-f*CFTR* about 5×10^9 DRP/ μ L and AV2/2.tg83-f*CFTR*(HA) about 3×10^9 DRP/ μ L). Polarized CF HAE were cultured at an ALI and infected at the relatively high multiplicity of infection (MOI) of about 10^5 DRP/cell (10^{11} DRP of each rAAV2 vector per insert). At 10 days following infection, the level of *CFTR* expression was determined by measuring short circuit
30 current (Isc), as described in Zhang et al. (2004) and Fisher et al. (2011). Figure 3B shows a typical Isc trace following infection of CF HAE with AV2/2.tg83-f*CFTR* or AV2/2.tg83-f*CFTR*-HA. Amiloride and DIDS were first applied to block non-*CFTR* chloride channels and ENaC-mediated sodium currents, and then cAMP agonists (IBMX and forskolin) were used to induce *CFTR* activity. The changes in Isc following the
35 addition of IBMX and forskolin (Δ Isc_{IBMX & Forsk}) and the subsequent addition of the *CFTR* inhibitor GlyH101 (Δ Isc_{GlyH}) were used to evaluate the function of *CFTR*. These results clearly demonstrated that functional complementation of *CFTR* activity in CF HAE is greater following infection with AV2/2.tg83-f*CFTR* than with AV2/2.tg83-f*CFTR*-HA (Figure 3B). The mean Δ Isc_{IBMX & Forsk} and Δ Isc_{GlyH} values from these experiments are
40 summarized in Figure 3C. *CFTR*-mediated cAMP-inducible Cl⁻ currents produced by AV2/2.tg83-f*CFTR*(HA) were only 3.6% those in a non-CF HAE ALI cultures, but still

above background levels ($p < 0.01$). By contrast, infection with AV2/2.tg83-f*CFTR* produced 10-fold greater cAMP-inducible Cl^- currents than AV2/2.tg83-f*CFTR*(HA) and achieved about 30% *CFTR* activity of non-CF HAE ALI cultures. These results demonstrate that the cutoff for retaining *CFTR* function is very narrow when producing oversized rAAV genomes, and that vector functionality does not depend only on the efficiency of packaging DRPs. Furthermore, these studies suggest that incorporation of the 100 nucleotide F5 enhancer into AV2/2.tg83-f*CFTR*, with a total genome size of 5.04 kb, may have a significant negative impact on function of the genome.

Effective packaging of a functional ferret *CFTR* mini gene into rAAV

Next, the possibility of using a shortened ferret *CFTR* minigene was explored, to further reduce the genome size of a rAAV-*CFTR* vector, and to allow for incorporation of the F5 enhancer. A human *CFTR* minigene (*CFTR* ΔR) with a 156 bp partial deletion of the R-domain (encoding amino acids 708-759) has been reported to retain most of the chloride-channel activity of the full-length protein (Ostedgaard et al., 2002; Ostedgaard et al., 2011). A f*CFTR* ΔR minigene was created by deleting the 159 bp homologous sequence encoding amino acids 708-760 at the corresponding position of the human protein, and produced two additional vectors: AV2/2.tg83-f*CFTR* ΔR (4.778 kb) and AV2/2.tg83-f*CFTR* ΔR (HA) (4.877 kb). This pair of vectors allowed for the examination not only the function of the f*CFTR* minigene in CF HAE ALI cultures, but also the impact of the HA-tag insertion in the f*CFTR* gene. Analysis of $\Delta \text{Isc}_{\text{ClBMX \& Forsk}}$ and $\Delta \text{Isc}_{\text{GlyH}}$ responses for these two viruses demonstrated that both AV2/2.tg83-f*CFTR* and AV2/2.tg83-f*CFTR*(HA) produced substantial *CFTR*-mediated Cl^- currents following infection of the CF HAE ALI cultures (Figure 3C). However, the HA-tagged form produced about 20% less Cl^- current than AV2/2.tg83-f*CFTR* ΔR . This finding is consistent with rAAV vectors of 4.88 kb having only about 25% of the functional activity of vectors 4.68 kb (Dong et al., 1996). Alternatively, the HA-tag may itself influence *CFTR* function in the context of the R-domain deletion, although in the context of full-length *CFTR* this ECL4 HA-tag has no impact on Cl^- channel function (Glozman et al., 2009; Fisher et al., 2011). Despite the larger genome size of AV2/2.tg83-f*CFTR* (4.9437 kb), this vector produced about 30% more *CFTR*-mediated current than its shorter counterpart AV2/2.tg83-f*CFTR* ΔR (4.778 kb) (Figure 3C). This reduction in Cl^- channel activity of f*CFTR* ΔR is similar to that reported for h*CFTR* ΔR (Ostedgaard et al., 2002). However, given the potential for reduced functionality of larger vector genomes, the impact of the R-domain deletion on the function of the ferret *CFTR* protein is likely greater than that for human *CFTR*.

To establish the impact of genome length on packaging of the rAAV vectors tested, the integrity of the viral genome was examined, using alkaline-denatured agarose gel electrophoresis followed by Southern blotting (Figure 4A). This analysis revealed that the smallest vector genome (i.e. that of AV2.tg83-f*CFTR* ΔR , 4.778 kb) could be distinguished from the other three viruses based on its faster migration through the gel (AV2.tg83-f*CFTR* ΔR is 99 nucleotides shorter than the AV2.tg83-f*CFTR* ΔR (HA)

vector). However, AV2.tg83-*fCFTR*(HA) (5.036 kb), AV2.tg83-*fCFTR* (4.937 kb) and AV2.tg83-*fCFTR* Δ R(HA) (4.887 kb) could not be distinguished from one another on the basis of this analysis. Given that it should be possible to visualize differences of both 149 nucleotides (AV2.tg83-*fCFTR*(HA) vs. AV2.tg83-*fCFTR* Δ R(HA)) and 99 nucleotides (AV2.tg83-*fCFTR*(HA) vs. AV2.tg83-*fCFTR* Δ R(HA), and AV2.tg83-*fCFTR*(HA) vs. AV2.tg83-*fCFTR*), these findings were interpreted as support for the notion that viral genomes larger than that of AV2.tg83-*fCFTR* Δ R(HA) (4.887 kb) tend to incur deletions that compromise *CFTR* transgene expression.

The notion that deletion occurs in the context of longer genomes was further supported by the hybridization of viral genomes with two sets of plus and minus strand oligonucleotide probes at the center of *CFTR* cDNA, the tg83 promoter, and synthetic poly-A sequences (Figure 4B). Results from this analysis demonstrated viral DNA from the largest AV2.tg83-*fCFTR*(HA) vector incurred deletions at both the 5' ends of positive and minus strand genomes. By contrast, the 3' end of positive and minus strand AV2.tg83-*fCFTR*(HA) genomes remained intact, consistent with packaging of single stranded AAV genomes from the 3' to 5' direction. The fact that the strength of hybridization at the tg83 promoter (for positive strand), and the polyA sequence (for minus strand), was lower than that of hybridization to the *fCFTR* cDNA suggested that these deletions were not restricted to the ITR region (i.e., that the damage extended into the *CFTR* expression cassette). Such deletions were not observed in the second longest vector, AV2.tg83-*fCFTR*, therefore, the *CFTR* expression cassette in this vector most likely still remains intact, although partial deletions in the ITR region likely occur as suggested from the viral DNA migration on denatured agarose gel. While deletions in the ITR regions may not directly influence expression of the *CFTR* transgene, they may impact the stability of viral genomes and thus indirectly influence *CFTR* expression. These results, together with the functional analysis, led to the conclusion that the *fCFTR* Δ R cDNA without the HA-tag would be best suited for testing the impact of the F5 enhancer on rAAV-mediated *CFTR* complementation.

The synthetic F5tg83 promoter improves rAAV-mediated *CFTR* complementation.

Next, the pAV2.F5tg83-*fCFTR* Δ R proviral plasmid was generated and AV2/2.F5tg83-*fCFTR* Δ R virus with a genome size of 4.87 kb was produced. The efficiency of this virus for complementing function of the *CFTR* channel following infection of polarized CF HAE was compared to that of the enhancer-less counterpart vector (AV2.tg83-*fCFTR* Δ R). Results from this analysis demonstrated that incorporation of the F5 enhancer greatly improved the *CFTR*-mediated Cl⁻ currents (Figure 5). At two weeks following basolateral infection at an MOI of 5x10⁴ DRP/cell, cAMP-induced *CFTR*-mediated Cl⁻ currents were 3.5-fold greater for AV2/2.F5tg83-*fCFTR* Δ R than for AV2/2.tg83-*fCFTR* Δ R, and the former was 89% of those observed in non-CF primary HAE. A similar improvement in *CFTR* function (4.8-fold) was observed with AV2/2.F5tg83-*fCFTR* Δ R following apical infection, but in this case the efficiency of transduction was significantly lower, as previously reported for this serotype. At the

reduced MOI of 1×10^4 DRP/cell basolaterally, AV2/2.F5tg83-fCFTR Δ R produced 69% of the CFTR current generated by this vector at a 5-fold higher MOI, suggesting that complementation of CFTR function approached saturation in the latter case. Thus, when one compares the effectiveness of AV2/2.F5tg83-fCFTR Δ R (1×10^4 DRP/cell) and AV2/2.tg83-fCFTR Δ R (5×10^4 DRP/cell) vectors in the context of optimal infection (i.e., basolateral) and non-saturating conditions, incorporation of the F5 enhancer improved the vector efficacy by 13.5-fold. This level of increase in current is consistent with the increase in expression observed with the analogous luciferase expression vectors (Figure 2D, 19.6-fold).

Given the apparent saturation of CFTR currents at the highest MOI (5×10^4 DRP/cell) following basolateral infection with AV2/2.F5tg83fCFTR Δ R, the kinetics of CFTR expression were evaluated at an intermediate MOI (2×10^4 DRP/cell). Measurements were carried out 3 and 10 days following infection of CF HAE with AV2/2.F5tg83-fCFTR Δ R and AV2/2.tg83-fCFTR Δ R. Results from this analysis demonstrated that, in the context of the F5 enhancer, the onset of CFTR-mediated Cl⁻ currents was more rapid than in its absence (Figure 6A). In fact, CFTR currents were maximal by 3 days after infection with AV2/2.F5tg83-fCFTR Δ R, whereas currents increased 3.6-fold between 3 and 10 days after infection with AV2/2.tg83-fCFTR Δ R. To more directly compare transcriptional activity between these vectors, the ferret CFTR mRNA was examined by real-time RNA-specific reverse transcriptase PCR (RS-PCR), a method that prevents amplification of vector-derived DNA products and was previously applied in detecting the CFTR mRNA from rAAV-infected cells and tissues (Zhang et al., 2004; Gerard et al., 2003). Analyses of the RS-PCR results, after normalization to ferret GAPDH transcripts, demonstrated 6.4-fold and 17.1-fold higher levels of fCFTR mRNA following infection with AV2.F5tg83-fCFTR Δ R vs. AV2/2.tg83-fCFTR Δ R, at the 3 and 10 day time points, respectively (Figure 6B). The 10-fold increase in CFTR mRNA observed between 3 and 10 days after infection confirms that CFTR currents were saturated by 3 days post-infection. Thus, at the transcriptional level, incorporation of the F5 enhancer increased CFTR expression 17.1-fold, closely mirroring the results observed with luciferase expression vectors (Figure 2D, 19.6-fold).

Discussion

rAAV vectors have attracted considerable interest with respect to human gene therapy, but its inherently small genome (4.679 kb) is a significant challenge for the delivery of large genes such as CFTR. Although several laboratories have attempted to rationally design short enhancers and promoters for use in rAAV vectors, this approach has yet to yield robust expression of CFTR in the airway. In the present study, an entirely empirical approach was taken by screening synthetic enhancers for their effectiveness in the delivery of reporter gene expression in step-wise fashion – in plasmids, proviral vectors, and viral vectors. While the main goal was to develop rAAV vectors for delivering CFTR to the airway, a similar approach may prove useful for gene

therapy efforts tackling the delivery of other large genes (e.g., Factor VIII and dystrophin) that necessitate the use of short promoters.

Production of an oversized rAAV genome is known to lead to random deletions at the 5' end of the encapsidated single stranded genomes (Kapranov et al., 2012), but the functional integrity of rAAV vector genomes that approach the accepted maximum capacity of rAAV (about 5.0 kb) has not been thoroughly investigated. The current study provides, in the context of *CFTR*-expressing rAAV vectors, evidence that functionality of the rAAV genome begins to decline well below this 5.0 kb cut off. Evidence in support of this includes a reduction in *CFTR* function for 4.877 kb vs. 4.778 kb genomes (Figure 3C) and the lack of differences in the migration of 4.877-5.036 kb single-stranded genomes when visualized on alkaline gels (Figure 4A). Additionally, the largest *CFTR* vector (5.036 kb) incurred deletion in about 30% of genomes that extend beyond the 5' ITR and into the promoter (in the case of the positive strand) or polyA region (in the case of the minus strand). This suggests that damage to the *CFTR* expression cassette may be responsible for the significant impairment of function of *CFTR* delivered by this vector. While the oligo probes used only detected deletions in 30% of genomes for this largest construct, the 90% reduction in *CFTR* chloride current between 4.937 vs 5.036 kb vectors suggests that a much larger percentage of genomes incur functional deletions and that ITR deletions may also impair vector performance.

The present findings seem inconsistent with previous observations of an only 4-fold change in transgene expression between rAAV vectors that are 4.7 kb and 5.2 kb in size (Wu et al., 2010). However, in this earlier study the stuffer sequence used to expand the vector was positioned between the expression cassette and the ITR, and deletions of the stuffer sequence would likely have less of an impact on the transcriptional activity of the transgene. The current study of the AAV-*CFTR* vector instead employed a short synthetic promoter and poly-A signal, and small deletions within these short transcriptional regulatory elements would be expected to greatly influence gene expression. Since DNase resistant particle titer is typically used to confirm effective packaging of rAAV genomes, small 5'-end deletions could have a significant impact on functionality of oversized rAAV vectors.

The empirical approach that was used to screen synthetic 100 bp enhancers for the ability to improve rAAV-mediated transgene expression in the airway yielded several important observations: 1) Enhancer activity differed by cell lines and also the state of cell differentiation. 2) Enhancer activity was influenced by the AAV ITRs and might also be influenced by the sequence of gene of interest (in this study, the 3' half of the ferret *CFTR* cDNA coding region). 3) Enhancer activity in the case of rAAV infection was generally similar to that in the context of proviral vector, though with subtle differences. 4) Infection of human and ferret airways with viral vectors revealed some differences in enhancer function (most notably for AV2/2.F1tg83luc, Figures 2D and 2E). These results indicate that although transfection with proviral plasmid is suitable for initial screens of synthetic enhancers, performing such a screen in unpolarized primary airway

cultures may not produce the same patterns of gene expression observed following AAV infection of polarized airway cultures.

Through this screen, a 100 bp synthetic enhancer (F5) was identified that significantly improves the transcriptional activity of an 83 bp synthetic promoter (tg83), in polarized cultures of both primary human and ferret airway epithelial cells, as well as in ferret lung and trachea *in vivo*. The ferret *CFTR* minigene lacking a 53 amino acid portion of the R domain (f*CFTR* Δ R) retained about 70% of wild type f*CFTR* function, similar to the 80% function retained by a previously reported, analogous h*CFTR* Δ R construct (Ostedgaard et al., 2002). Nevertheless, this was greatly compensated by the increased transgene expression from AV2.F5tg83-f*CFTR* Δ R, as the use of the shortened minigene spares 150 bp space to allow for the incorporation of the F5 enhancer. In the context of a rAAV vector, the F5 enhancer significantly improved tg83-driven *CFTR* mRNA expression (17.1-fold) at 10 days post-infection of CF HAE relative to the AV2/2.tg83-f*CFTR* Δ R vector, which lacks this enhancer. This increase in *CFTR* mRNA expression from AV2/2.F5tg83-f*CFTR* Δ R correlated well with the 19.6-fold improvement in *CFTR*-mediated currents made possible by this vector, and resulted in production of about 89% of the cAMP-mediated Cl⁻ currents observed in non-CF HAE. Of note, a ceiling on the level of functional correction that can be achieved with respect to the changes in I_{sc} was found. In the time-course studies, maximal correction of I_{sc} in CF HAE was achieved by 3 days post-infection, with the about 10 fold increase in *CFTR* mRNA by 10 days post-infection yielding no improvement in Cl⁻ currents (Figure 6). These findings provide important insight into evaluating the functionality of rAAV-*CFTR* vectors: dose responses of the vector are needed for accurate comparison of vector designs. The ceiling on *CFTR* currents could reflect self-limiting cell biology (e.g., control over the total amount of *CFTR* on the plasma membrane), or aberrant trafficking of *CFTR* to the basolateral membrane at higher levels of expression (Farmen et al., 2005).

In summary, a rAAV-*CFTR* vector was generated that provides high-level expression suitable for use in lung gene therapy studies in the CF ferret model. Moreover, the present findings suggest that small synthetic enhancers and promoters may be useful tools for optimizing the design of rAAV vectors for the delivery of large transgenes.

Summary

As discussed herein, small synthetic enhancer/promoter combination, sized about or less than 200 bp, can be used in rAAV vector to deliver effective transgene expression of a large transgene expression; in this study, the gene is *CFTR*. As also discussed herein, empirical approach to screen a set of 100-mer synthetic enhancer elements for their ability to augment reporter expression from a short 83-bp synthetic promoter (tg83p) in lung airway tissue. Partial sequence of the gene of interest (in the study is *CFTR*) is included to the reporter vector to maximize the effect to screen the best enhancer sequence. The screening was conducted in step-wise fashion – in

plasmids, proviral vectors, and rAAV vectors, and in different cell/tissue levels— in monolayer (non-polarized) cultures of human airway cell lines and primary ferret airway cell, in polarized cultures of human and ferret airway epithelia at an air-liquid interface (ALI) and ferret airway *in vivo*. The enhancer activity differs by cell lines and state of cell differentiation, as well as is influenced by the AAV ITRs and by the sequence of gene of interest. Thus, the effects of an enhancer in the context of plasmid transfection may be different from that in the context of rAAV transduction. The *in vivo* effects of a particular enhancer may not be predictable from its behaviors demonstrated in culture cell lines. This, the screening needs to be conducted in different cell/tissue levels and in a step-wise fashion – in plasmids, proviral vectors, and rAAV vectors to warrant the success.

Three of synthetic enhancers (F1, F5, and F10) were found significantly increase the transcription of tg83p for luciferase transgene in the context of plasmid transfection. The F5tg83 promoter, the 183 bp combination of F5 enhancer and tg83p, was the most efficient promoter in human and ferret ALI cultures, leading to 19.6-fold and 57.5-fold increases reporter expression, respectively, over the enhancer-less counterpart. The F5tg83 promoter also produced the highest level of transgene expression in the ferret airway *in vivo*. When the F5tg83 promoter was used to transcribe the 4.2 kb *CFTR* minigene (*CFTR* ΔR) in a rAAV vector, it yielded an about 17-fold increase in vector derived *CFTR* mRNA transcription and significantly improved Cl⁻ currents in human CF ALI cultures, compared to the vector using tg83p only.

The enhancer/promoter combinations for lung epithelium (e.g., F5tg83) may not necessarily be as useful for other organs/tissue. For example, when AAV vectors harboring a luciferase reporter gene driven by F5tg83 or F10tg83 were used to infect different tissues/organs of the digestive system, F5tg83 demonstrated the strongest promoter activity in pancreas, gallbladder and liver, whereas F10tg83 outperformed F5tg83 in small intestine (Figures 7A-7B).

Although the studies were focused on identifying strong synthetic enhancer/promoter sequence using for efficiently expressing *CFTR* in lung/airway tissue, the screen approach can be used for any desired cell types, tissues and organs *in vitro* and *in vivo*.

Thus, the use of short enhancer elements (about 100-mer synthetic oligonucleotide sequences consisting of 10-mer repeats) was found to enhance gene expression from a minimal promoter in rAAV vectors. These 100 bp enhancer elements were previously identified for their ability to activate transcription directed by the CMV immediate-early (IE) minimal promoter in cell lines (Schlabach et al., 2010). It was hypothesized that enhancers that are most potent in activating transcription could be used to enhance activity of the synthetic tg83 promoter in airway cells in the context of rAAV vectors. Eight combinations of the tg83 promoter and 100 bp synthetic enhancers were tested, and one designated as F5 efficiently was found to enhance the transcription from the tg83 promoter in polarized airway cells (*in vitro*) derived from both

humans and ferrets, as well as in the ferret airway (*in vivo*). Using the F5tg83 promoter and the ferret *CFTR* minigene of partial deletion at R domain (*fCFTR* Δ R), a rAAV vector (AV2/2.F5tg83-*fCFTR* Δ R) was found and its ability to correct CFTR-mediated Cl⁻ transport in CF ALI cultures tested.

5

Example 2

AV.F5Tg83-hCFTR Δ R was tested for hCFTR expression in the newborn and mature ferret airway. An endpoint of these analyses was the ratio of transgene-derived human CFTR (hCFTR) to that of endogenous ferret CFTR (*fCFTR*) mRNA. In 3 day old newborn ferrets (Figure 9), AV.F5Tg83-CFTR Δ R led to 240% greater expression of

10 human CFTR compared with endogenous (ferret) CFTR following gene delivery to the lung.

Given that the phenotype of ferret airway epithelia and the secretions in the airway change as the lungs mature, it was evaluated whether AV.F5Tg83-CFTR Δ R transduces the mature ferret airway and the promoter remains active. To this end, the

15 ability of AV.F5Tg83-CFTR Δ R to transduce the lung of 1 month old ferrets was evaluated. In 1 month old mature ferrets (Figure 10), AV.F5Tg83-CFTR Δ R led to 300% greater expression of human CFTR compared with endogenous (ferret) CFTR following gene delivery to the lung. Furthermore, the ratio of human to ferret CFTR was approximately one in the nasal passage. These findings from newborn and mature

20 ferrets suggest that the F5Tg83 promoter robustly expresses the CFTR transgene in the lung *in vivo*.

References

- Aitken et al., Chest, 123:792 (2003).
- 25 Aitken et al., Hum Gene Ther., 12:1907 (2001).
- Carter, Hum Gene Ther., 16:541 (2005).
- Conrad et al., Gene Ther., 3:658 (1996).
- Daya & Berns, Clin. Microb. Rev., 21:583 (2008).
- Ding et al., Gene Ther., 12:873 (2005).
- 30 Ding et al., Mol. Ther., 13:671 (2006).
- Dong et al., Hum. Gene Ther., 7:2101 (1996).
- Duan et al., Hum. Gene Ther., 9:2761 (1998).
- Duan et al., J. Clin. Invest., 105:1573 (2000).
- Farmen et al., Am. J. Physiol. Lung Cell Mol. Physiol., 289:1123 (2005).
- 35 Fisher et al., J. Biol. Chem., 287:21673 (2012).
- Flotte et al., J. Biol. Chem., 268:3781 (1993).
- Flotte, Curr. Opin. Mol. Ther., 3: 497 (2001).
- Flotte, et al., J. Biol. Chem., 268:3781 (1993).
- Gerard et al., Gene Ther., 10:1744 (2003).
- 40 Glozman et al., J. Cell Biol., 184:847 (2009).
- Griesenbach et al., Virus Adapt. Treat., 2:159, (2010).

- Griesenback & Alton, Adv. Drug Deliv. Rev., **61**:128 (2009).
- Kapranov et al., Hum. Gene Ther., **23**:46 (2012).
- Karp et al., Methods Mol. Biol., **188**:115 (2002).
- Li et al., Mol. Ther., **17**:2067 (2009).
- 5 Liu et al., Am. J. Respir. Cell Mol. Biol., **36**:313 (2007).
- Liu et al., Gene Ther., **14**:1543 (2007).
- Liu et al., Mol. Ther., **15**:2114 (2007).
- Moss et al., Hum. Gene Ther., **18**:726 (2007).
- Mueller & Flotte, Clin. Rev. Allergy Immunol., **35**:164 (2008).
- 10 Olivier et al., J. Clin. Invest., **122**:3755 (2012).
- Ostedgaard et al., Proc. Natl. Acad. Sci. USA, **102**:2952 (2005).
- Ostedgaard et al., Proc. Natl. Acad. Sci. USA, **108**:2921 (2011).
- Ostedgaard et al., Proc. Natl. Acad. Sci. USA, **99**:3093 (2002).
- O'Sullivan & Freedman, Lancet, **373**:1891 (2009).
- 15 Riordan et al., Science, **245**:1066 (1989).
- Rommens et al., Science, **245**:1059 (1989).
- Rowe et al., N. Engl. J. Med., **352**:1992 (2005).
- Schlabach et al., Proc. Natl. Acad. Sci. USA, **107**:2538 (2010).
- Summer-Jones et al., Gene Therapy for Cystic Fibrosis Lung Disease,
 20 Birkhauser Basel, Basel (2010).
- Sun et al., Am. J. Pathol., **184**:1309 (2014).
- Sun et al., Am. J. Respir. Cell Mol. Biol., **50**:502 (2014).
- Sun et al., J. Clin. Invest., **118**:1578 (2008).
- Sun et al., J. Clin. Invest., **120**:3149 (2010).
- 25 Wagner et al., Hum. Gene Ther., **13**:1349 (2002).
- Welsch, FASEB. J., **4**:2718 (1990).
- Welsh et al., In The Metabolic and Molecular Bases of Inherited Disease, eds.
 McGraw-Hill, New York, p. 3799 (1995).
- Wu et al., Mol. Ther., **14**:316 (2006).
- 30 Wu et al., Mol. Ther., **18**:80 (2010).
- Yan et al., Hum. Gene Ther., **24**:786 (2013).
- Yan et al., Hum. Gene Ther., **26**:334 (2015).
- Yan et al., J. Virol., **76**:2043 (2002).
- Yan et al., J. Virol., **78**:2863 (2004).
- 35 Yan et al., Mol. Ther., **21**:2181 (2013).
- Zabner et al., Am J. Physiol. Lung Cell Mol. Physiol., **284**:844 (2003).
- Zhang et al., Mol. Ther., **10**:990 (2004).
- Zhang et al., Proc. Natl. Acad. Sci. USA, **95**:10158 (1998).
- 40 All publications, patents and patent applications are incorporated herein by
 reference. While in the foregoing specification, this invention has been described in

relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details herein may be varied considerably without departing from the basic principles of the invention.

5

WHAT IS CLAIMED IS:

1. An isolated recombinant parvovirus vector comprising a synthetic enhancer comprising plurality of enhancer sequences operably linked to a promoter.
5
2. The recombinant parvovirus vector of claim 1, wherein each of the plurality of enhancer sequences has the same sequence.
3. The recombinant parvovirus vector of claim 1, wherein at least two of the
10 plurality of enhancer sequences have a different sequence.
4. The recombinant parvovirus vector of any one of claims 1 to 3, wherein the plurality of enhancer sequences has 2 up to 20, 2 up to 15 or 2 up to 10, of the enhancer sequences in tandem.
15
5. The recombinant parvovirus vector of any one of claims 1 to 4, wherein at least one of the enhancer sequences has no more than 15 bases.
6. The recombinant parvovirus vector of any one of claims 1 to 5, wherein the
20 plurality of enhancer sequences has one or more P53 binding sites, one or more NRF-1 binding sites or one or more CREB binding sites, or a combination thereof.
7. The recombinant parvovirus vector of claim 1, wherein the synthetic enhancer comprises F1, F5 or F10.
25
8. The recombinant parvovirus vector of claim 1, wherein the synthetic enhancer has at least one enhancer sequence with at least 80% nucleotide sequence identity to F1, F5 or F10.
9. The recombinant parvovirus vector of claim 1, wherein the synthetic enhancer has at least one enhancer sequence with at least 90% nucleotide sequence identity to F1, F5 or F10.
30
10. The recombinant parvovirus vector of claim 1, wherein the synthetic enhancer has at least one enhancer sequence with at least 95% nucleotide sequence identity to F1, F5 or F10.
35
11. The recombinant parvovirus vector of any one of claims 1 to 10, wherein the plurality of enhancers is up to about 120 nucleotides in length.
40

12. The recombinant parvovirus vector of any one of claims 1 to 10, wherein the plurality of enhancers is up to about 150 nucleotides in length.
13. The recombinant parvovirus vector of any one of claims 1 to 10, wherein the plurality of enhancers is up to about 100 nucleotides in length.
14. The recombinant parvovirus vector of any one of claims 1 to 13, wherein the promoter is a synthetic promoter.
15. The recombinant parvovirus vector of claim 14, wherein the promoter is tg83.
16. The recombinant parvovirus vector of any one of claims 1 to 13, wherein the promoter is a heterologous promoter.
17. The recombinant parvovirus vector of any one of claims 1 to 16 which is a bocavirus or an adeno-associated virus vector.
18. The recombinant parvovirus vector of any one of claims 1 to 17, wherein the promoter is operably linked to an open reading frame.
19. The recombinant parvovirus vector of claim 18, wherein the open reading frame encodes a prophylactic or therapeutic gene product.
20. The recombinant parvovirus vector of any one of claims 1 to 19, wherein the combination of the plurality of enhancer sequences and the promoter is no more than 200 nucleotides in length.
21. The recombinant parvovirus vector of any one of claims 1 to 19, wherein the combination of the plurality of enhancer sequences and the promoter is no more than 150 nucleotides in length.
22. The recombinant parvovirus vector of any one of claims 1 to 19, wherein the combination of the plurality of enhancer sequences and the promoter is no more than 250 nucleotides in length.
23. The recombinant parvovirus vector of any one of claims 1 to 22 wherein the synthetic enhancer and promoter have at least 80%, 85%, 90%, 95%, 98% 99% or more nucleic acid sequence identity to one of SEQ ID Nos.24-30.
24. A method to express a transgene in a cell, comprising: introducing a composition comprising a recombinant parvovirus vector comprising a synthetic



enhancer comprising a plurality of enhancer sequences operably linked to a promoter operably linked to a transgene to a eukaryotic cell so as to express the transgene in the cell.

- 5 25. A method to express a transgene in a mammal, comprising introducing to a mammal a composition comprising a recombinant parvovirus vector comprising a synthetic enhancer comprising a plurality of enhancer sequences operably linked to a promoter operably linked to a transgene so as to express the transgene in cells of the mammal.
- 10 26. The method of claim 24 or 25, wherein the expression of the transgene is enhanced by at least 2-, 5-, 10-, or 15-fold or more relative to a corresponding parvovirus vector that lacks the synthetic enhancer.
- 15 27. The method of any one of claims 24 to 26 wherein the plurality of enhancer sequences has two or more P53 binding sites, two or more NRF-1 binding sites, or two or more CREB binding sites.
- 20 28. The method of any one of claims 25 to 27 wherein the composition is injected.
- 25 29. The method of any one of claims 25 to 27 wherein the composition is intranasally administered.
- 30 30. The method of any one of claims 24 to 29, wherein each of the plurality of enhancer sequences has the same sequence.
- 35 31. The method of any one of claims 24 to 30, wherein at least two of the plurality of enhancer sequences have a different sequence.
- 30 32. The method of any one of claims 24 to 31, wherein the plurality of enhancer sequences has 2 up to 20, 2 up to 15 or 2 up to 10, of the enhancer sequences in tandem.
- 35 33. The method of any one of claims 24 to 32, wherein at least one of the enhancer sequences has no more than 15 bases.
34. 34. The method of any one of claims 24 to 33, wherein the synthetic enhancer comprises F1, F5 or F10.


35. The method of any one of claims 24 to 33, wherein the synthetic enhancer has at least one enhance sequence with at least 80%, at least 90% nucleotide sequence identity to F1, F5 or F10, or at least 95% nucleotide sequence identity to F1, F5 or F10.
- 5 36. The method of any one of claims 24 to 35, wherein the plurality of enhancers is up to about 100, up to about 120 or up to about 150 nucleotides in length.
37. The method of any one of claims 24 to 36, wherein the promoter is a synthetic promoter.
- 10 38. The method of claim 37, wherein the promoter is tg83.
39. The method of any one of claims 24 to 36, wherein the promoter is a heterologous promoter.
- 15 40. The method of any one of claims 24 to 39, wherein the vector is a bocavirus or an adeno-associated virus vector.
41. The method of any one of claims 24 to 40, wherein the transgene encodes a prophylactic or therapeutic gene product.
- 20 42. The method of any one of claims 24 to 41, wherein the combination of the plurality of enhancer sequences and the promoter is no more than 150, no more than 200 or no more than 250 nucleotides in length.
- 25 43. The method of any one of claims 24 to 42 wherein the synthetic enhancer and promoter have at least 80%, 85%, 90%, 95%, 98% 99% or more nucleic acid sequence identity to one of SEQ ID Nos.24-30.
- 30 44. An isolated vector comprising a synthetic enhancer comprising plurality of enhancer sequences operably linked to a promoter.
45. The vector of claim 44, wherein each of the plurality of enhancer sequences has the same sequence.
- 35 46. The vector of claim 44, wherein at least two of the plurality of enhancer sequences have a different sequence.
47. The vector of any one of claims 44 to 46, wherein the plurality of enhancer sequences has 2 up to 20, 2 up to 15 or 2 up to 10, of the enhancer sequences in tandem.
- 40

48. The vector of any one of claims 44 to 47, wherein at least one of the enhancer sequences has no more than 15 bases.
- 5 49. The vector of any one of claims 44 to 48, wherein the plurality of enhancer sequences has one or more P53 binding sites, one or more NRF-1 binding sites or one or more CREB binding sites, or a combination thereof.
- 10 50. The vector of claim 44, wherein the synthetic enhancer has at least one enhancer sequence with at least 80%, 90% or 95% nucleotide sequence identity to F1, F5 or F10.
- 15 51. The vector of any one of claims 44 to 50, wherein the plurality of enhancers is up to about 100, 120 or 150 nucleotides in length.
52. The vector of any one of claims 44 to 51, wherein the promoter is a synthetic promoter.
- 20 53. The vector of claim 52, wherein the promoter is tg83.
54. The vector of any one of claims 44 to 53, wherein the promoter is operably linked to an open reading frame.
55. The vector of claim 54, wherein the open reading frame encodes a prophylactic or therapeutic gene product.
- 25 56. The vector of any one of claims 44 to 55, wherein the combination of the plurality of enhancer sequences and the promoter is no more than 150, 200 or 250 nucleotides in length.
- 30 57. The vector of any one of claims 44 to 56 wherein the synthetic enhancer and promoter have at least 80%, 85%, 90%, 95%, 98% 99% or more nucleic acid sequence identity to one of SEQ ID Nos.24-30.
58. The vector of any one of claims 44 to 57 which is a plasmid.


1/35



C



D



A

B

Figure 1

2/35






Figure 3



4/35

Figure 4







Figure 6






Figure 7A




Figure 7B

Identifier	Binding Factor	Sequence (Search Pattern)
HS\$A11COL_02		GTGGTTAGC
MOUSE\$IAP_01		GTGGT
MOUSE\$IAP_03	EBP-80	GTGGT
EBV\$IR4_04	R	CACCAC
EBV\$IR4_05	R	CACCAC
HS\$PR264_01	c-Myb	GGTGAG
HS\$APOA2_06		TCACC
TDNA\$NOS_01	ASF-1, OBF3.1, TGA1a, TGA1b	TGAGC
DROME\$SUBX_08	Zeste	TGAGCG
DROME\$E74_07	Zeste	TGAGCG
DROME\$E74_08	Zeste	TGAGCG
DROME\$WHLO_04	Zeste	TGAGCG
DROME\$ZESTE_02	Zeste	TGAGCG
DROME\$SUBX_06	Zeste	CGCTCA
DROME\$EVE_04	GAGA factor	CGCTC
DROME\$EVE_08	GAGA factor	CGCTC
DROME\$EVE_10	GAGA factor	CGCTC
ASS\$PAX4_29	Pax-4a	CATTCCCAGACG
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT

Figure 8A

10/35

Identifier	Binding Factor	Sequence (Search Pattern)
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC

Figure 8B

11/35

Identifier	Binding Factor	Sequence (Search Pattern)
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
HS\$APAF1_01	p53	CGACAAGCCC
AS\$HOXA3_13	HOXA3	CATGTTGGG
AS\$FTZ_56	Ftz	CCGACA
HSV1\$GD_01	ICP4	CCGAC
AT\$COR15A_01	ANT, CBF1, CBF2, CBF3	CCGAC
AT\$RD29B_01	CBF1	CCGAC
AT\$RD29A_01	CBF1, DREB1 A, DREB2 A	CCGAC
AT\$COR78_01	ANT, CBF1, CBF2, CBF3	CCGAC
AT\$COR15B_01	CBF1, CBF2, CBF3	CCGAC
HS\$CGB_03		CGGGCATCCTG
HS\$CEIP_02	LXR-alpha, LXR-beta, RXR-alpha,	CGGGCA
HS\$CYCD1_15	Sp1, Sp2, Sp3, Sp4	GCCCCG
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha,	GGGCA

Figure 8C

12/35

Identifier	Binding Factor	Sequence (Search Pattern)
	Sp1	
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
ASPNS\$ABAA_03	abaA	CATTCT
ASPNS\$ABAA_04	abaA	CATTCT
ASPNS\$ABAA_05	abaA	CATTCT
ASPNS\$BRLA_03	abaA	CATTCT
ASPNS\$RODA_05	abaA	CATTCT
ABAA\$CONS_01	abaA	CATTCT
ASPNS\$BRLA_05	abaA	CATTCT
ASPNS\$YA_02	abaA	AGAATG
ISHSF_01	HSF	AGAAN
F\$HSF_01	HSF	AGAAN
SV\$SV40_37		CTGGG
RAT\$IGFBP2_03	Sp1	TGGGCGTGTG
SV\$SV40_63	T-Ag	TGGGC
Y\$HOP1_01		TGGGCGGCT
RAT\$BMHC_04	NFe	TGACGCCCA
MOUSE\$GLUT4_03	Sp1	GGGCGT
HS\$U2SN_04	Sp1	ACGCCC
HS\$CD11B_01	Sp1	CGCCC
AS\$PAX4_29	Pax-4a	CATTCCCAGACG
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$TAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NFI_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT

Figure 8D

Identifier	Binding Factor	Sequence (Search Pattern)
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$TAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC

Figure 8E

Identifier	Binding Factor	Sequence (Search Pattern)
Y\$MAL61_04	MIG1	AATTG
RAT\$TH_03	ARIX	AATTGA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWRKY_01	WRKY3, WRKY4	TTGAC
AS\$WRKY_01	WRKY1, WRKY2	TTGAC
AS\$WRKY_02	WRKY1, WRKY2	TTGAC
AS\$WRKY_03	WRKY1, WRKY2	TTGAC
AS\$WRKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	TGACG
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3, c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	TGCGTCA
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
AS\$PAX2_67	Pax-2.1, Pax- 2.2	AATAAATG C

Figure 8F

Identifier	Binding Factor	Sequence (Search Pattern)
RAT\$GLU_04		TATAT
HS\$HH4_08	HNF-D, HNF-M, HNF-P, TFIID, TMF	TATAT
MOUSE\$SRF_03	SRF (504 AA)	TATAT
RAT\$GLU_04		TATAT
HS\$HH4_08	HNF-D, HNF-M, HNF-P, TFIID, TMF	TATAT
MOUSE\$SRF_03	SRF (504 AA)	TATAT
RAT\$DBH_01	ARIX, c-Fos, c-Jun, CREB, CREMtau	TGCGTCAT TA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWKY_01	WRKY3, WRKY4	TTGAC
AS\$WKY_01	WRKY1, WRKY2	TTGAC
AS\$WKY_02	WRKY1, WRKY2	TTGAC
AS\$WKY_03	WRKY1, WRKY2	TTGAC
AS\$WKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6,ZAP1	TGACG
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3,	TGCGTCA

Figure 8G

Identifier	Binding Factor	Sequence (Search Pattern)
	c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
RAT\$DBH_01	ARIX, c-Fos, c-Jun, CREB, CREMtau	TGCGTCATTA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWRKY_01	WRKY3, WRKY4	TTGAC
AS\$WRKY_01	WRKY1, WRKY2	TTGAC
AS\$WRKY_02	WRKY1, WRKY2	TTGAC
AS\$WRKY_03	WRKY1, WRKY2	TTGAC
AS\$WRKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	TGACG
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HBV\$HBVE_27	CRE-BP1, CREB, pX	TGACGCAA
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3,	TGCGTCA

Figure 8H

Identifier	Binding Factor	Sequence (Search Pattern)
	c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB,	CGTCA
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
ASS\$NCX_33	Ncx	ACGTAAAT TG
HS\$EGFR_14		CAAAT
MAIZE\$PMS1_01		CAAAT
HS\$IGH_04		ATTTG
Y\$MAL61_04	MIG1	AATTG
RAT\$TH_03	ARIX	AATTGA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWKRY_01	WRKY3, WRKY4	TTGAC
AS\$WKRY_01	WRKY1, WRKY2	TTGAC
AS\$WKRY_02	WRKY1, WRKY2	TTGAC
AS\$WKRY_03	WRKY1, WRKY2	TTGAC
AS\$WKRY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	TGACG
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HBV\$HBVE_27	CRE-BP1,	TGACGCAA

Figure 8I

18/35

Identifier	Binding Factor	Sequence (Search Pattern)
	CREB, pX	
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3, c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	TGCGTCA
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
HS\$EGFR_14		CAAAT
MAIZE\$PMS1_01		CAAAT
DROME\$SNA_12	Twi	CAAATG
HS\$IGH_04		ATTTG
XENLA\$AC_05	EMF1, MyoD	CATTTG
MOUSE\$ACRG_01	MyoD	CATTTG
HS\$IRF1_02	IPCS-BF	AAATGAC GGC
HS\$GMCSF_03	YY1	CATTT
MOUSE\$IL4_01	NF-CLE0a, NF-CLE0b	TCATTT
HS\$UPA_05	UEF-1	CATGACAG C
HS\$FN_05	PEBP2	ATGACCGC AA
HS\$UPA_06	Pbx-1a, Pbx-1b, Pbx-2, PKNOX1, PKNOX2, UEF-3	TGACAG
AS\$MEIS1_01	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_03	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_04	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_05	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_06	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_07	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_08	Meis-1a, Meis-1b	TGACAG

Figure 8J

Identifier	Binding Factor	Sequence (Search Pattern)
	Meis-1b	
AS\$MEIS1_14	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1_19	Meis-1a, Meis-1b	TGACAG
AS\$MEIS1AHOXA9_01	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_02	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_03	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_04	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_05	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_06	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_09	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_10	HOXA9, Meis-1a	TGACAG
AS\$MEIS1AHOXA9_13	HOXA9, Meis-1a	TGACAG
AS\$MEIS1BHOXA9_01	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_02	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_03	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_04	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_05	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_06	HOXA9, Meis-1b	TGACAG
AS\$MEIS1BHOXA9_07	HOXA9, Meis-1b	TGACAG
POT\$PR10a_01	PBF-1, PBF-2 (p24)	TGACA
AS\$TGIF_01	TGIF	TGTCA
AS\$TGIF_02	TGIF	TGTCA
AS\$TGIF_03	TGIF	TGTCA
AS\$TGIF_04	TGIF	TGTCA
AS\$TGIF_05	TGIF	TGTCA
AS\$TGIF_06	TGIF	TGTCA
AS\$TGIF_07	TGIF	TGTCA
AS\$TGIF_08	TGIF	TGTCA

Figure 8K

Identifier	Binding Factor	Sequence (Search Pattern)
AS\$TGIF_10	TGIF	TGTCA
AS\$TGIF_11	TGIF	TGTCA
AS\$TGIF_12	TGIF	TGTCA
AS\$TGIF_13	TGIF	TGTCA
AS\$TGIF_14	TGIF	TGTCA
AS\$TGIF_15	TGIF	TGTCA
HS\$D1A_01	Meis-2a, Meis-2b, Meis-2c, Meis-2d, TGIF	CTGTCA
AS\$MEIS1_11	Meis-1a, Meis-1b	CTGTCA
AS\$MEIS1_12	Meis-1a, Meis-1b	CTGTCA
POT\$PR10a_01	PBF-1, PBF-2 (p24)	TGTCA
HS\$GG_12	NF-E	CTGTC
DROME\$EVE_10	GAGA factor	CTGTC
MOUSE\$M2EAK_03	NF-Y	CAGCA
MOUSE\$THY1_06		CAGCAA
RAV0\$RAV0_01	C/EBPalpha	GCAAG
AMV\$AMV_02	C/EBPalpha	CTTGC
XENLA\$ACY_01	SRF	AAGAT
XENLA\$ACY_01	SRF	ATCTT
HS\$GG_26	GATA-1	AGATTG
MOUSE\$BMG_04	GATA-1	AATCT
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWRKY_01	WRKY3, WRKY4	TTGAC
AS\$WRKY_01	WRKY1, WRKY2	TTGAC
AS\$WRKY_02	WRKY1, WRKY2	TTGAC
AS\$WRKY_03	WRKY1, WRKY2	TTGAC
AS\$WRKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a,TGA1 b, TGA2,	TGACG

Figure 8L

Identifier	Binding Factor	Sequence (Search Pattern)
	TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HBV\$HBVE_27	CRE-BP1, CREB, pX	TGACGCAA
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3, c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	TGCGTCA
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
ASS\$NCX_33	Ncx	ACGTAAAT TG
HS\$EGFR_14		CAAAT
MAIZE\$PMS1_01		CAAAT
HS\$IGH_04		ATTTG
Y\$MAL61_04	MIG1	AATTG
RAT\$TH_03	AR1X	AATTGA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
TDNA\$NOS_01	ASF-1, OBF3.1, TGA1a, TGA1b	TGAGC
DROME\$UBX_08	Zeste	TGAGCG
DROME\$E74_07	Zeste	TGAGCG
DROME\$E74_08	Zeste	TGAGCG
DROME\$WHLO_04	Zeste	TGAGCG
DROME\$ZESTE_02	Zeste	TGAGCG
DROME\$UBX_06	Zeste	CGCTCA
DROME\$EVE_04	GAGA factor	CGCTC
DROME\$EVE_08	GAGA factor	CGCTC
DROME\$EVE_10	GAGA factor	CGCTC

Figure 8M

Identifier	Binding Factor	Sequence (Search Pattern)
MOUSE\$MT1_06	MTF-1	TGCGCTC
HS\$EGFR_14		CAAAT
MAIZE\$PMS1_01		CAAAT
HS\$IGH_04		ATTG
Y\$MAL61_04	MIG1	AATTG
RAT\$TH_03	ARIX	AATTGA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$WRKY_01	WRKY3, WRKY4	TTGAC
AS\$WRKY_01	WRKY1, WRKY2	TTGAC
AS\$WRKY_02	WRKY1, WRKY2	TTGAC
AS\$WRKY_03	WRKY1, WRKY2	TTGAC
AS\$WRKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	TGACG
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$INS_04	CREB	TGACG
HS\$PL_12		TGACG
HBV\$HBVE_27	CRE-BP1, CREB, Px	TGACGCAA
HS\$CFOS_11	AP-1, ATF	TGCGTCA
HS\$PK_02		TGCGTCA
HS\$PK_03	AP-1, ATF3, c-Fos, c-Jun, CRE-BP1, CREB, CREBbeta	TGCGTCA
HS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA

Figure 8N

23/35

Identifier	Binding Factor	Sequence (Search Pattern)
BOVIN\$PPTA_01	C/EBPdelta, CRE-BP2	TGCGTCA
RAT\$PDYN_01	CREB	TGCGTCA
HS\$EGFR_14		CAAAT
MAIZE\$PMS1_01		CAAAT
HS\$IGH_04		ATTTG
ASS\$ATHB1_26	ATHB-1	CAATTAAT TG
ASS\$NKX61_02	Nkx6-1	TTAATTT
ASS\$ATHB1_26	ATHB-1	CAATTAAT TG
YSSUC2_02	MIG1	AATTA
RAT\$DBH_01	ARIX, c-Fos, c-Jun, CREB, CREMtau	AATTA
DROME\$EN_01	En, Eve, Ftz, Prd, Zen-1, Zen-2	TCAATCAA TT
DROME\$EN_01	En, Eve, Ftz, Prd, Zen-1, Zen-2	TCAATTAA AT
DROME\$EN_04	En, POU2F2 (Oct-2.1)	TCAATTAA AT
ASS\$FTZ_47	Ftz, Prd, Zen-1, Zen-2	TCAATTAA AT
ASS\$EN_01	En	TCAATTAA AT
EN\$CONS	Abd-A, Abd-B, BarH1, Cfla, Cut, Ems, En, Lab, PDM-1, Zfh-1, Zfh-2	TCAATTAA AT
Y\$MEL1_02	MIG1	ATTAA
CHICK\$MGF_01	Gbx2	ATTAA
DROME\$EN_05	En	TCAATTAA A
DROME\$ADH_29		CTCAATTA AT
CHICK\$MGF_02	Gbx2	TTAAT
UBX\$CONS_02	Ubx	TTAATKG
MOUSE\$HOXC8_04		TTAATTG
CHICK\$MGF_02	Gbx2	TTAAT
ASS\$NKX61_01	Nkx6-1	TTAATTG
ASS\$NKX61_02	Nkx6-1	TTAATTG
ASS\$NKX61_03	Nkx6-1	TTAATTG

Figure 80

24/35

Identifier	Binding Factor	Sequence (Search Pattern)
AS\$NKX61_05	IPF1, Nkx6-1	TTAATTG
AS\$NKX61_06	Nkx6-1	TTAATTG
AS\$NKX61_08	Nkx6-1	TTAATTG
AS\$NKX61_09	Nkx6-1	TTAATTG
AS\$NKX61_10	Nkx6-1	TTAATTG
YSMEL1_02	MIG1	ATTAA
BOVIN\$RHO_02	Crx	CAATTAA
CHICK\$MGF_01	Gbx2	ATTAA
YSSUC2_02	MIG1	AATTA
RAT\$DBH_01	ARIX, c-Fos, c-Jun, CREB, CREMtau	AATTA
YSMAL61_04	MIG1	AATTG
RAT\$TH_03	ARIX	AATTGA
PSAM\$U7SN_04		ATTGA
HS\$EGFR_15		TCAAT
AS\$TWRKY_01	WRKY3, WRKY4	TTGAC
AS\$WRKY_01	WRKY1, WRKY2	TTGAC
AS\$WRKY_02	WRKY1, WRKY2	TTGAC
AS\$WRKY_03	WRKY1, WRKY2	TTGAC
AS\$WRKY_04	WRKY1, WRKY2	TTGAC
AT\$RLK4_01	WRKY18	TTGAC
AT\$RLK4_02	WRKY18	TTGAC

Figure 8P

Identifier	Binding Factor	Sequence (Search Pattern)
HS\$A11COL_02		GTGGTTAGC
MOUSE\$IAP_01		GTGGT
MOUSE\$IAP_03	EBP-80	GTGGT
EBV\$IR4_04	R	CACCAC
EBV\$IR4_05	R	CACCAC
HS\$PR264_01	c-Myb	GGTGAG
HS\$APOA2_06		TCACC
TDNA\$NOS_01	ASF-1, OBF3.1, TGA1a, TGA1b	TGAGC
DROME\$SUBX_08	Zeste	TGAGCG
DROME\$E74_07	Zeste	TGAGCG
DROME\$E74_08	Zeste	TGAGCG
DROME\$WHLO_04	Zeste	TGAGCG
DROME\$ZESTE_02	Zeste	TGAGCG
DROME\$SUBX_06	Zeste	CGCTCA
DROME\$EVE_04	GAGA factor	CGCTC
DROME\$EVE_08	GAGA factor	CGCTC
DROME\$EVE_10	GAGA factor	CGCTC
AS\$PAX4_29	Pax-4a	CATTCCCAGACG
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT

Figure 8Q

26/35

Identifier	Binding Factor	Sequence (Search Pattern)
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalp ha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalp ha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$STAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA

Figure 8R

Identifier	Binding Factor	Sequence (Search Pattern)
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
HS\$APAF1_01	p53	CGACAAGCCC
AS\$HOXA3_13	HOXA3	CATGTTGGG
AS\$FTZ_56	Ftz	CCGACA
HSV1\$GD_01	ICP4	CCGAC
AT\$COR15A_01	ANT, CBF1, CBF2, CBF3	CCGAC
AT\$RD29B_01	CBF1	CCGAC
AT\$RD29A_01	CBF1, DREB1A, DREB2A	CCGAC
AT\$COR78_01	ANT, CBF1, CBF2, CBF3	CCGAC
AT\$COR15B_01	CBF1, CBF2, CBF3	CCGAC
HS\$CGB_03		CGGGCATCCT G
HS\$CETP_02	LXR- alpha, LXR-beta, RXR- alpha	CGGGCA
HS\$CYCD1_15	Sp1, Sp2, Sp3, Sp4	GCCCCG
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
ASP\$ABAA_03	abaA	CATTCT
ASP\$ABAA_04	abaA	CATTCT
ASP\$ABAA_05	abaA	CATTCT
ASP\$BRLA_03	abaA	CATTCT
ASP\$RODA_05	abaA	CATTCT
ABAA\$CONS_01	abaA	CATTCT
ASP\$BRLA_05	abaA	CATTCT

Figure 8S

Identifier	Binding Factor	Sequence (Search Pattern)
ASPN\$YA_02	abaA	AGAATG
I\$HSF_01	HSF	AGAAN
F\$HSF_01	HSF	AGAAN
SV\$SV40_37		CTGGG
RAT\$IGFBP2_03	Sp1	TGGGCGTGTG
SV\$SV40_63	T-Ag	TGGGC
Y\$HOP1_01		TGGGCGGCT
RAT\$BMHC_04	NFe	TGACGCCCA
MOUSE\$GLUT4_03	Sp1	GGGCGT
HS\$U2SN_04	Sp1	ACGCCC
HS\$CD11B_01	Sp1	CGCCC
AS\$PAX4_29	Pax-4a	CATTCCCAGA CG
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$TAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
RAT\$SPI23_02	C/EBPalpha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
RAT\$TAT_06	NRF-1	CATGCGCAG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
MOUSE\$PIDD_01	p53	GGACATGTCT
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC

Figure 8T

Identifier	Binding Factor	Sequence (Search Pattern)
RAT\$SPI23_02	C/EBPalp ha	CCCAGAAAT
AS\$TGIF_09	TGIF	TGTCT
CHICK\$BAG_04		TCTGGGCA
CHICK\$BAG_09	CTF	TCTGGGCA
SV\$SV40_37		CTGGG
SV\$SV40_63	T-Ag	TGGGC
CHICK\$BAG_03		GGGCA
RAT\$NF1_01	LF-A1	GGGCA
HS\$CATHD_01	ER-alpha, Sp1	GGGCA
RAT\$VEGF_01	ER-alpha, ER-beta	GGGCA
CHICK\$BAG_03		TGCCC
RAT\$VEGF_02	ER-alpha, ER-beta	TGCCC
AS\$STAT5A_44	STAT5A	TTCTCGACA
ISHSF_01	HSF	AGAAN
FSHSF_01	HSF	AGAAN
HS\$TERT_01	c-Myc	CACCGT
WHEAT\$H4_01	ssDBP-1, ssDBP-2	CCACGTCACC G
CREB\$CONS_02	CREB, CREBbeta , deltaCRE B	GNTGACGY
AS\$BZIP911_27	bZIP911	GGTGACGTGT AC
AS\$BZIP911_28	bZIP911	GGTGACGTGT AC
AS\$BZIP911_30	bZIP911	GGTGACGTGT AC
HS\$APOA2_06		TCACC
AD\$MLP_10	USF	CACGTGACC
AD\$E4_02	E4F1	GTGACGT
AD\$E4_03	CRE-BP1, E4F1	GTGACGT
AD\$E4_05	E4F1	GTGACGT
AD\$SE1A_14	ATF	GTGACGT
AD\$SE1A_16	ATF	GTGACGT
AD\$SE1A_21	ATF	GTGACGT
HS\$MIB7_03		GTGACG
HS\$P53_03	Pax-2, Pax-5, Pax-8	GTGAC
HS\$MMP1_06		GTCAC

Figure 8U

Identifier	Binding Factor	Sequence (Search Pattern)
CAMV\$35SR_01	ASF-1, OBF4, OBF5, SARP, TGA1, TGA1a, TGA1b, TGA2, TGA2.1, TGA2.2, TGA3, TGA6, ZAP1	TGACG
HS\$GHA_03	GR, GR-alpha, GR-beta	TGACGT
PIG\$UPA_02	CREB	TGACG
PIG\$UPA_03	CREB, CREBbeta	TGACG
HS\$VIP_04	ATF	TGACGT
CAMV\$35SR_03	HBP-1, HBP-1a, HBP-1a(1), HBP-1a(c14), HBP-1b, HBP-1b(c1)	TGACGT
HS\$INS_04	CREB	TGACG
RAT\$TH2A_01		TGACGT
AT\$DBP_01	GBF1, HBP-1a, HBP-1b, OBF3.1, OBF3.2, OBF4, OBF5, TGA1, TGA3, TGA6	TGACGT
PEA\$LEGA_01	HBP-1a, HBP-1b	TGACGT
HS\$PL_12		TGACG
HT1\$HTLV1_20	TAF-I, TAF-II, Tax	TGACGT

Figure 8V

Identifier	Binding Factor	Sequence (Search Pattern)
BZIP910\$CONS_01	bZIP910	TGACGTG
BZIP910\$CONS_02	bZIP910	TGACGT
AD\$E4_16	ATF, atf1, ATF3, c-Jun, CRE-BP1, CREB, deltaCREB, EivF, TREB-1	ACGTCA
RAT\$TH_02	ATF	ACGTCA
HSS\$VIP_01	c-Fos, c-Jun, CRE-BP1, CREB	CGTCA
TDNA\$NOS_02	HBP-1, HBP-1a, HBP-1b	ACGTCA
RAT\$TH2B_04		ACGTCA
RICE\$NR1_01	HBP-1a, HBP-1b	ACGTCA
Y\$LPD1_02	ATF	ACGTCA
HS\$ENO1_01	HIF-1	GACGTG
AT\$GST6_02	OBF4	GACGTG
RICE\$EM_01	OSBZ8, TRAB1	ACGTG
RICE\$EM_02	OSBZ8	ACGTG
HS\$ET1_03	HIF-1	GCACGT
AS\$mEMBP_15	EmBP-1a	CACGT
MOUSE\$MT1_01	Sp1	TGCAC
MOUSE\$MT1_01	Sp1	TGCAC
RAT\$CYTOP_04	AhR, Arnt	CACGC
DAUCE\$DC3_04	DPBF-1, DPBF-2	CACGCG
AS\$AHRARNT_50	AhR, Arnt	GCGTG
AS\$DSC1_01	DSC1	ACGCGT
Y\$CDC9_02	DSC1	ACGCGT
Y\$POL1_01	MCBF	ACGCGT

Figure 8W




Figure 9B

Figure 9A




Figure 9D

Figure 9C




Figure 10B

Figure 10A




Figure 10D

Figure 10C

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/021124

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N15/86 A61K48/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EP0-Internal, Sequence Search, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2014/168953 A1 (UNIV IOWA RES FOUND [US]; KC CT FOR TECHNOLOGY COMMERCIALIZATION [US];) 16 October 2014 (2014-10-16) examples 1-5	1-58
X	----- ZIYING YAN ET AL: "Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers", HUMAN GENE THERAPY, vol. 26, no. 6, 1 June 2015 (2015-06-01), pages 334-346, XP55308423, US ISSN: 1043-0342, DOI: 10.1089/hum.2015.001 the whole document ----- -/--	1-58

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 May 2017

Date of mailing of the international search report

22/05/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Sprinks, Matthew

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/021124

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. R. SCHLABACH ET AL: "Synthetic design of strong promoters", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 6, 9 February 2010 (2010-02-09), pages 2538-2543, XP55064057, ISSN: 0027-8424, DOI: 10.1073/pnas.0914803107 figure 3 -----	1-58

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2017/021124

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2014168953 A1	16-10-2014	AU 2014251099 A1	12-11-2015
		CA 2909085 A1	16-10-2014
		CN 105431170 A	23-03-2016
		EP 2983707 A1	17-02-2016
		HK 1217916 A1	27-01-2017
		JP 2016518121 A	23-06-2016
		US 2016068821 A1	10-03-2016
		WO 2014168953 A1	16-10-2014
